Donate

RESEARCH DOCUMENTS

Jim Allison, Ph.D.

Brief Biography of Jim Allison, Ph.D.

Dr. James Allison is regental professor and chair in the Department of Immunology, the Executive Director of the Immunotherapy Platform, and Director of the Parker Institute for Cancer Immunotherapy at the University of Texas MD Anderson Cancer Center. He is a pioneer in the field of T cell biology and continues to push the boundaries of our understanding of immunity and cancer immunotherapy. Over the course of his career he has uncovered the fundamental mechanisms by which T cells are activated to eliminate foreign threats and by which they are regulated to avoid autoimmunity. He discovered the identity of the elusive T cell antigen receptor (TCR) and determined its structure (1, 2). It soon became apparent that activation of the TCR was insufficient to fully activate the T cell immune response. Dr. Allison’s lab determined that CD28 is the major costimulatory molecule on the T cell surface that when bound to its cognate receptor B7 on the surface of antigen presenting cells allows full activation of naïve T cells and prevents anergy (3). Additionally, he showed that introduction of the B7 molecule on tumor cells led them to be recognized and eliminated by the immune system (4). His lab, along with Jeff Bluestone’s, resolved a major controversy by demonstrating that another T cell receptor CTLA-4 by opposing CD28-mediated costimulation (5). He further showed that activation of the TCR increased expression of CTLA-4 on the T cell surface.

Allison saw an opening to apply his basic immunology findings to the treatment of cancer. He hypothesized that as tumor cells died, their cell debris would be ingested by antigen presenting cells, which would then display their unique antigens and activate T cells through a process called cross-presentation. At this point it became a race; either those T cells would become fully activated through the CD28/B7 interaction and eliminate the cancer cells or they would be inhibited through the CTLA-4/B7 interaction, resulting in tumor immune tolerance. His lab generated a monoclonal antibody that blocked CTLA-4 and tested it in tumor-bearing mice. The results were astounding; the tumors completely disappeared (6). Through a great deal of persistence, he convinced a pharma partner to develop a humanized anti-CTLA-4 antibody, which became ipilimumab. In 2011, ipilimumab was approved for the treatment of metastatic melanoma as the first immune checkpoint therapy. Immune checkpoint inhibitors have since been approved for therapy against a number of targets, most notably blocking the PD-1/PD-L1 axis, in a growing variety of cancer types.

These findings paved the wave for the entire emerging field of immune checkpoint therapy for cancer and earned Dr. Allison a share of the 2018 Nobel Prize in Physiology and Medicine. Among many honors, he is a member of the National Academies of Science and Medicine and received the received the Lasker-Debakey Clinical Medical Research award in 2015.

 

  1. Allison JP, McIntyre BW, & Bloch D (1982) Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol 129(5):2293-2300.
  2. McIntyre BW & Allison JP (1983) The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell 34(3):739-746.
  3. Harding FA, McArthur JG, Gross JA, Raulet DH, & Allison JP (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356(6370):607-609.
  4. Townsend SE & Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259(5093):368-370.
  5. Krummel MF & Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459-465.
  6. Leach DR, Krummel MF, & Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734-1736.

 

 

Allison Laboratory Research Programs

The results of immune checkpoint therapy (ICT) have been remarkable for patients who respond. About 20% of metastatic melanoma patients treated with ipilimumab remain cancer-free 15 years out and counting (1). Combination ipilimumab and nivolumab (anti-CTLA-4 and anti-PD-1) raises the response rate to >55% (2), and it is likely that the responses will be as durable as those seen with ipilimumab. Since ipilimumab was approved as the first ICT in 2011, we have seen approvals of anti-CTLA-4 and anti-PD-1 therapies for a number of cancers, including lung cancer, renal cell carcinoma, bladder cancer, hepatocellular carcinoma, triple negative breast cancer, and colorectal cancer.

However, limitations remain. Only a fraction of patients with cancers known to be sensitive, respond to ICT, and some cancers, such as pancreatic cancer and glioblastoma, have not been shown to respond at all. Extensive efforts are now underway to develop new ICT combination therapies for those patients and cancers that do not respond. At present, there are ~2000 combination trials, the majority involving anti-PD-1. Most are limited to seeking clinical signal, and because they are rarely accompanied by tumor biopsies to characterize possible changes in the tumor microenvironment, they provide no knowledge on how the therapies interact or insight into rational design of future trials.

The overarching goal of Dr. Allison’s work is to address these limitations and bring effective immunotherapies to more patients and cancers. He and his collaborators have established an iterative bench to bedside and back model to improve our understanding of the mechanisms of immune checkpoints in the tumor immune response and to derive rational combinations involving ICTs.

Mechanisms of immune checkpoints

A major impediment to the development of rational immune therapies is our incomplete understanding of the mechanisms by which monotherapies and combinations affect the many populations of immune cells that populate the tumor microenvironment. Using preclinical models, Allison’s lab showed that inhibition of CTLA-4 and PD-1 therapies expand unique populations of T cells; CTLA-4 blockade expands CD4 and CD8 T cells while PD-1 blockade preferentially expands previously exhausted CD8 T cells (3). The finding provided a potential explanation as to the mechanism through which combined CTLA-4/PD-1 therapy provides higher response rates than either monotherapy. Allison’s team later showed that combined CTLA-4/PD-1 blockade works through a unique population of T cells not visible in either monotherapy rather than through an additive effect (4); exhausted T cells disappear and direct activation of effector cells is seen. These findings highlight the complexity of accurate determination of rational combination therapies. Ongoing work seeks to expand this work to profile the effects of modulation of other immune checkpoints including ICOS, TIGIT, VISTA, and TIM3 on the tumor immune response and determine the consequences of their various double and triple combinations.

Discovery of new immune checkpoints 

The tumor immune response is mediated by a network of different cellular elements of both the innate and adaptive immune responses. Discovery of additional targets for modulation of the tumor immune response both on T cells and other cells will help expand our repertoire of potential elements for combination therapy. In recent work, a ligand for toll-like receptor 1 and 2 (TLR1/2), which activates the innate immune system, was found to increase the efficacy of CTLA-4 blockade in a mouse tumor model through an interesting mechanism. TLR1/2 activation increased depletion of intratumoral regulatory T cells (Tregs), which suppress the immune response, by increasing the levels of FC receptor-g 4 (FCR-g) on tumor macrophages (5). We also found that the LILRB4 inhibitory receptor is highly expressed on tumor microenvironment immune cells and is a potential target for immunotherapy.  We plan to continue to explore the role of LILRB4 and TLR function in the immune response to specific tumors. Modulating these pathways will provide potential new combination treatment options for patients in fight against cancer.

Immunotherapy Platform

We propose to conduct studies in patients and pre-clinical models to evaluate mechanisms of response and resistance, which will enable the development of novel combination strategies to drive mechanisms of response and overcome mechanisms of resistance.  To this end we have established at the MD Anderson Cancer Center the Immunotherapy Platform, which is comprised of clinical investigators across 18 departments; scientists with expertise in immunology, tumor biology, pathology, genomic medicine, animal models and bioinformatics; and administrative teams who manage the informed consent process for an umbrella lab protocol that allows for collection of human samples from all of the patients in clinical trials. To date we have been involved in about 100 clinical trials. Patient samples, consisting of longitudinal tumor biopsies, bone marrow samples, stool and blood, using a variety of cutting-edge techniques, including high dimensional flow cytometry, whole exome, bulk and single cell RNA sequencing, and multiplex immunohistochemical analysis. The data from patient samples are then correlated with clinical outcomes to formulate hypotheses regarding mechanisms of response and resistance, with additional research studies conducted in pre-clinical models to test the hypotheses and move new ideas into the next set of clinical trials.

An example of our approach is our recent work in castrate resistant prostate cancer (CRPC).  Some CRPC patients responded to anti-CTLA-4 in early trials, but a phase III trial for castration-resistant prostate cancer failed to reach significance. There were to responders to PD-1 in a Phase I trial, so Bristol Meyers-Squibb their program in CRPC, concluding that CRPC was “non-immunogenic.” However, our studies of pre-surgical samples through the showed that while untreated prostate cancer is an immunological “desert” with scant infiltration with immune cells, treatment with anti-CTLA-4 induces robust tumor immune cell infiltration.  However this is accompanied by upregulation of immune checkpoints, including PD-L1. PD-1 induces no tumor immune cell infiltration, suggesting that anti-CTLA-4 is ineffective due to induction of the PD-1/PD-L1 axis, while anti-PD-1 is ineffective due to a lack of tumor infiltrating T cells (6).  A resulting pilot trial of combination ipilimumab and nivolumab yielded some complete responses; an expanded trial is now underway.

Based on our work in both the clinic and the lab, we’ve demonstrated the dynamic changes that occur within the immune response as a result of treatment with anti-CTLA-4 and anti-PD1/PD-L1. For example, treatment of patients with anti-CTLA-4 can lead to compensatory changes to control the immune response, such as increased expression of VISTA, another inhibitory immune checkpoint, and increased expression of EZH2, an epigenetic mechanism that acts to stabilize the transcription factor FoxP3 for development of regulatory T cells that inhibit immune responses (7). We demonstrated that VISTA is highly expressed on myeloid cells and in human pancreatic cancer, a tumor type that has not responded well to current anti-CTLA-4 or anti-PD-1 strategies (6). We propose that VISTA is an immunotherapy target for the treatment of pancreatic cancer. Furthermore, we tested our hypothesis that a novel combination of anti-CTLA-4 plus an EZH2-inhbitor would improve anti-tumor responses in a pre-clinical model. Our pre-clinical data provided the rationale for a new clinical trial with combination therapy of anti-CTLA-4 plus EZH2-inhibitor.

We propose to continue evaluation of patients’ samples collected from the 100+ clinical trials that are currently ongoing, as well as in new clinical trials that we initiate as a result of data generated from our studies. The iterative process of moving quickly between the clinic and the lab and then back to the clinic is the strength of the Immunotherapy Platform. Data from the Immunotherapy Platform will continue to provide scientific rationale for novel combination clinical trials to enhance the success of immune checkpoint therapy and improve clinical outcomes for cancer patients.  We will use our umbrella consent protocol to obtain longitudinal tumor and blood specimens from patients on combination checkpoint inhibitors trials, including those of multiple checkpoint, or checkpoints in combination with more conventional cancer therapies (chemotherapy, radiation therapy, therapies targeting mutations that drive cancer, epigenetic factors) in order to obtain mechanistic data to drive development of rational approaches to cancer treatment.

 

  1. Schadendorf D, et al. (2015) Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 33(17):1889-1894.
  2. Larkin J, et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373(1):23-34.
  3. Wei SC, et al. (2017) Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170(6):1120-1133 e1117.
  4. Wei SC, et al. (2019) Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity 50(4):1084-1098 e1010.
  5. Sharma N, Vacher J, & Allison JP (2019) TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. Proc Natl Acad Sci U S A 116(21):10453-10462.
  6. Gao J, et al. (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-555.
  7. Goswami S, et al. (2018) Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-3818.

 

 

CURRICULUM VITAE

James P. Allison, Ph.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Chair, Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Vivian L. Smith Distinguished Chair in Immunology, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX

Regental Professor, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Executive Director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX

Deputy Director, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Director, Center for Cancer Immunological Research (CCIR), The University of Texas MD Anderson Cancer Center, Houston, TX

Director, Parker Institute for Cancer Immunotherapy (PICI), The University of Texas MD Anderson Cancer Center, Houston, TX

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center

7455 Fannin Street

Unit Number: 901

Houston, TX 77054

Room Number: 1SCRB3.1035

Phone: (713) 563-3285

Fax: (713) 563-3276

Email: JAllison@mdanderson.org

EDUCATION

Degree-Granting Education

The University of Texas at Austin, Austin, TX, BS, 1969, Microbiology

The University of Texas at Austin, Austin, TX, PHD, 1973, Biological Sciences

Postgraduate Training

Postdoctoral Fellow, Department of Molecular Immunology, Scripps Clinic and Research Foundation, La Jolla, CA, 1974-1977

EXPERIENCE/SERVICE

Academic Appointments

Assistant Biochemist and Assistant Professor, Biochemistry, The University of Texas MD Anderson Cancer Center, Science Park, Smithville, TX, 1977-1983

Adjunct Assistant Professor, Zoology, The University of Texas at Austin, Austin, TX, 1979-1984

Associate Biochemist and Associate Professor, Biochemistry, The University of Texas MD Anderson Cancer Center, Science Park, Smithville, TX, 1983-1984

Visiting Scholar, Pathology, Stanford University School of Medicine, Stanford, CA, 1983-1984

Professor, Molecular and Cell Biology, Division of Immunology, University of California, Berkeley, Berkeley, CA, 1985-2004

Adjunct Professor, Medicine, Division of Rheumatology, University of California, San Francisco School of Medicine, San Francisco, CA, 1997-2004

Professor, Weill Cornell Medicine, New York, NY, 2004-2012

Professor, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-2018

Regental Professor, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018-present

Administrative Appointments/Responsibilities

Director, Cancer Research Laboratory, University of California, Berkeley, Berkeley, CA, 1985-2004

Division Head ad interim, Molecular and Cell Biology, Division of Immunology, University of California, Berkeley, Berkeley, CA, 1987-1989

Division Head, Molecular and Cell Biology, Division of Immunology, University of California, Berkeley, Berkeley, CA, 1989-1997

Co-Chair, Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, 1998-2000

Co-Chair, Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Graduate School of Medical Sciences, New York, NY, 2004-2012

Chair, Immunology Program, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, 2004-2012

Director, Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, 2006-2012

Chair, Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-present

Executive Director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-present

Associate Director, Center for Cancer Immunological Research (CCIR), The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-present

Deputy Director, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-present

Director, Parker Institute for Cancer Immunotherapy (PICI), The University of Texas MD Anderson Cancer Center, Houston, TX, 2016-present

Science Chair Representative to the Chief Academic Officer ad interim, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017-2018

Chief Scientific Advisor ad interim, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017-3/2019

Other Appointments/Responsibilities

Special Associate Member of the Graduate Faculty, The University of Texas at Austin, Austin, TX, 1980-1984

Investigator, Howard Hughes Medical Institute (HHMI), Chevy Chase, MD, 1997-2012

Attending Immunologist, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, 2004-2012

Endowed Positions

David H. Koch Chair in Immunologic Studies, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, 2004-2012

Vivian L. Smith Distinguished Chair in Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016-present

Institutional Committee Activities

Advisory Committee, Member, 2012-present

Institutional Research Executive Committee, Member, 2012-present

Strategic Faculty Hiring (SFH) Committee, Member, 2012-present

Promotion and Tenure Committee, Member, 2012-present

HONORS AND AWARDS

Merit Award, National Institutes of Health (NIH), 1986

CaP CURE Research Award, CaP CURE, 1998

Lecture Award, Earle A. Chiles Research Institute Visiting Professor, Oregon Health & Science University, 1998

Lecture Award, R.E. (Bob) Smith Lecture, The University of Texas MD Anderson Cancer Center, 1998

Lecture Award, 37th Annual J.S. and H.R. Blumenthal Memorial Lectureship in Allergy & Clinical Immunology, University of Minnesota, 1999

Centeon Award for Innovative Breakthroughs in Immunology, Aventis Behring GmbH, 2001

CaP CURE Research Award, CaP CURE, 2002

Outstanding Alumnus Award, The University of Texas at Austin Graduate School, 2002

Lecture Award, 19th Annual Apffel Memorial Lecture, Boston Cancer Research Association, 2004

Lecture Award, Marshak Lecture in Immunotherapy, Boston University Medical Center, 2005

William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, Cancer Research Institute (CRI), 2005

Lecture Award, 12th Annual Melvin L. Samuels Lectureship, The University of Texas MD Anderson Cancer Center, 2006

Lecture Award, Benacerraf Lecture, Harvard University, 2007

  1. Chester Stock Award for Distinguished Achievement in Biomedical Research, Memorial Sloan-Kettering Cancer Center (MSKCC), 2008

Dana Foundation Award in Human Immunology Research, American Association of Immunologists (AAI), 2008

Lecture Award, Peter Doherty Lecture, St. Jude Children’s Research Hospital, 2009

Lecture Award, 14th Annual Mavis P. Kelsey Lecture, Texas A&M Health Science Center, 2010

Richard V. Smalley, MD, Memorial Lectureship Award, International Society for Biological Therapy of Cancer, 2010

Advancement of Cancer Research Award, Gilda’s Club, 2011

Breakthrough Achievements in Translational Cancer Research, American Skin Association, 2011

Jacob Heskel Gabbay Award in Biotechnology and Medicine, Brandeis University, 2011

Lifetime Achievement Award, American Association of Immunologists (AAI), 2011

Roche Award, Cancer Immunology and Immunotherapy, 2011

Heath Memorial Award, The University of Texas MD Anderson Cancer Center, 2012

Lecture Award, 8th Annual Massachusetts General Hospital Award in Cancer Research, Massachusetts General Hospital, 2012

Lecture Award, Susan Swerling Lecture, Seminars in Oncology, Dana-Farber Cancer Institute, 2012

Lifetime Achievement Award, Molecular Targeted Therapy Group, 2012

Innovations Award in BioScience, Economist, 2013

Lloyd J. Old Award in Cancer Immunology, American Association for Cancer Research (AACR)-Cancer Research Institute (CRI), 2013

Novartis Award for Clinical Immunology, Novartis, 2013

Breakthrough Prize in Life Sciences, Breakthrough Prize Foundation, 2014

Canada Gairdner International Award, The Gairdner Foundation, 2014

Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Science, The University of Texas MD Anderson Cancer Center, 2014

Distinguished Alumnus Award, Texas Exes, 2014-2015

Distinguished Research in the Biomedical Sciences Award, Association of American Medical Colleges (AAMC), 2014

G.H.A. Clowes Memorial Award, American Association for Cancer Research (AACR), 2014

Giants of Cancer Care Award in Scientific Advances, Intellisphere Oncology Specialty Group, 2014

Lecture Award, Bruckner Foundation Lecture Series, Washington University, Pathology and Immunology, 2014

Lecture Award, Mike Hogg Distinguished Lecturer Series, The University of Texas at Austin, 2014

Lecture Award, The Alexander Bodini Foundation Prize for Scientific Excellence in Medicine Scientific Research Lecture Series, American-Italian Cancer Foundation, 2014

Louisa Gross Horwitz Prize, Columbia University, 2014

Meira and Shaul G. Massry Prize, The Meira and Shaul G. Massry Foundation, 2014

President’s Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center, 2014

Prize for Scientific Excellence in Medicine, American-Italian Cancer Foundation, 2014

Szent-Gyorgyi Prize for Progress in Cancer Research, National Foundation for Cancer Research (NFCR), 2014

Tang Prize for Biopharmaceutical Science, Tang Prize Foundation, 2014

Harvey Prize in Human Health, Technion, Israel Institute of Technology, 2015

Lasker-DeBakey Clinical Medical Research Award, The Lasker Foundation, 2015

Lecture Award, Alando J. Ballantyne Lectureship, The University of Texas MD Anderson Cancer Center, Department of Head and Neck Surgery, 2015

Lecture Award, Albert Einstein Oncology and Hematology Center Satellite, 2015

Lecture Award, International Symposium Immunostimulatory Monoclonal Lecture Series, 2015

Lifetime Achievement in Melanoma Research Award, Society for Melanoma Research, 2015

Medal of Honor for Basic Research, American Cancer Society (ACS), 2015

Paul Ehrlich and Ludwig Darmstaedter Prize, Paul Ehrlich Foundation, 2015

Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research, AACR, 2015

President’s Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center, Experimental Therapeutics, 2015

Science of Oncology Award, American Society of Clinical Oncology (ASCO), 2015

The Benvenuto Memorial Award, The University of Texas MD Anderson Cancer Center, Experimental Therapeutics, 2015

The Passano Award, The Passano Foundation, Inc., 2015

Distinguished Scientist Award, Association of American Cancer Institutes (AACI), 2016

Fudan Zhongzhi Science Award, Fudan University and Zhongzhi Enterprise Group, 2016

Honorary Award, The Hope Funds for Cancer Research, 2016

Honorary Doctorate, Icahn School of Medicine at Mount Sinai, 2016

Honorary Doctorate of Science, Rockefeller University, 2016

Lecture Award, Japanese Society of Medical Oncology (JSMO) International Symposium on Immuno-Oncology, 2016

Lecture Award, Robert J. Lefkowitz, MD, Distinguished Lecture, Duke University School of Medicine, 2016

Balzan Prize for Immunologic Approaches in Cancer Therapy, International Balzan Foundation, 2017

Lecture Award, 7th Annual Henry Mihich Lecture, Roswell Park Cancer Institute, 2017

Lecture Award, Han-Mo Koo Memorial Lectureship Award, Van Andel Research Institute, 2017

Lecture Award, Janeway Lecture, American Radium Society, Inc., 2017

Lecture Award, Mark S. Brower, M.D. Endowed Lecture in Hematology & Oncology, Weill Cornell Medicine, 2017

Lecture Award, Mellon Lecture, University of Pittsburgh, 2017

Sjoberg Prize for Cancer Research, Royal Swedish Academy of Sciences (RSAS), 2017

Warren Alpert Foundation Prize, Harvard Medical School, 2017

Warren Triennial Prize, Massachusetts General Hospital, 2017

Wolf Prize for Medicine, Wolf Foundation, 2017

2018 Nobel Prize in Physiology or Medicine, Nobel Assembly at Karolinska Institutet, Stockholm, Sweden, 2018

2018 Jessie Stevenson Kovalenko Medal for Outstanding Research in Medical Sciences, National Academy of Sciences (NAS), 2018

2018 UCL Prize Lecture in Clinical Science, University of College London, 2018

Albany Medical Center Prize in Medicine and Biomedical Research, Albany Medical Center, 2018

BBVA Foundation Frontiers of Knowledge Laureate, BBVA Foundation, 2018

Honorary Member, President’s Council, The New York Academy of Sciences, 2018-present

King Faisal International Prize, King Faisal Foundation, 2018

Mike Hogg Award and Lecture, The University of Texas MD Anderson Cancer Center, 2018

The Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson, 2018

2018 Health Hero, Lifetime Achievement Award, WebMD, 2019

2019 Luminary Award, Texas Healthcare & Bioscience Institute (THBI), 2019

RESEARCH

Grants and Contracts

Funded

Principal Investigator, Recruitment of Established Investigators, R1203, Cancer Prevention & Research Institute of Texas (CPRIT), 9/1/2012-2/28/2020, $9,500,014 ($1,900,003/year)

Co-Investigator, 1.2 months, Cancer Center Support (CORE) Grant – Immunology CCSG, 5P30CA016672-42, NIH/NCI, PI – Pisters, 7/1/2013-6/30/2019, $57,505 ($11,501/year)

Principal Investigator, 0.6 months, SIV: Strategic Collaboration Agreement, 51878, AbbVie, 9/30/2015-9/29/2020, $3,590,971 ($900,000/year)

Principal Investigator, 0.6 months, Collaboration Agreement – Immuno-Monitoring, 52368, Bristol-Myers Squibb Company, 12/22/2015-12/21/2019, $900,000 ($400,000/year)

Co-Investigator, 1.2 months, Genetics and Biology of Pancreatic Ductal Adenocarcinoma – Project 3: The Functional Contribution of Tumor Immunity to PDAC, 5P01CA117969-14, NIH/NCI, PI – DePinho, 4/1/2016-3/31/2021, $6,763,941 ($1,445,647/year)

Co-Investigator, 0.24 months, Cancer Center Support Grant (CCSG) Supplement – Immunotherapy Biomarkers, 5P30CA016672-42, NIH/NCI, PI – Pisters, 7/1/2016-6/30/2019 ($468,752/year)

Mentor, Effects of Anti-CTLA-4 and Anti-PD-1 on Memory T-Cell Differentiation, 53169, Cancer Research Institute (CRI), PI – Mok, 7/1/2016-6/30/2019, $173,500 ($58,500/year)

Co-Leader, 0.6 months, MD Anderson Cancer Center Prostate Cancer SPORE – Project 1: Integrating Ipilimumab Immunotherapy with Approved Treatment Strategies in CRPC, 5P50CA140388-08, NIH/NCI, PI – Logothetis/Thompson, 9/1/2016-8/31/2021, $7,432,635 ($1,637,993/year)

Other Significant Contributor, Delineating the Role of the Microbiome in Modulating Tumor & Host Immunity, SU2C-AACR-IRG-19-17, American Association for Cancer Research (AACR), PI – Wargo, 7/1/2017-6/30/2020, $681,818 ($256,623/year)

Co-Investigator, 0.12 months, Intercepting Pancreatic Cancer in High Risk Cohorts, 533938, American Association for Cancer Research (AACR)/SU2C, PI – Maitra, 12/1/2017-11/30/2021, $5,517,943 ($1,260,000/year)

Principal Investigator, Tang Fellowships in Cancer Immunotherapy, Tang Prize Foundation, 1/1/2018-12/31/2020, $166,628 ($55,543/year)

Mentor, Targeting the Immunosuppressive Compartment of the Prostate Cancer Bone Metastatic Microenvironment to Improve Clinical Outcomes, V Foundation, PI – Subudhi, 2/1/2018-2/1/2020, $200,000 ($100,000/year)

Other Significant Contributor, MDSC-Tumor Crosstalk in Prostate Cancer Progression and Castration Resistance, 5R00CA194289-04, NIH/NCI, PI – Wang, 3/6/2018-2/28/2021, $566,298 ($166,625/year)

Co-Principal Investigator, 0.12 months, SIV: Collaborative Agreement (Immunotherapy) Astellas, Astellas Pharma US Inc., PI – Sharma, 3/29/2018-3/28/2021, $2,400,000 ($800,000/year)

Collaborator, Diet, Mental Health, and the Microbiome in Response to Immunotherapy, Melanoma Research Foundation, PI – Cohen, 5/1/2018-4/30/2021, $900,000 ($300,000/year)

Co-Investigator, 0.12 months, Targeting B7-H3 (CD276)-Mediated Immunomodulatory Function in AML Using Novel Monoclonal Antibodies, Anonymous Donor Foundation, PI – Battula, 9/1/2018-8/31/2020, $173,912 ($86,956/year)

Co-Mentor, Novel Therapeutic Approaches Targeting Tumor Suppressor Deficiencies in Advanced Prostate Cancer, 1K99CA226360-01A1, NIH/NCI, PI – Zhao, 9/1/2018-8/31/2023, $678,084 ($105,605/year)

Other Significant Contributor, The Molecular and Immune Evolution in the Progression of Lung Neoplasia to Invasive Adenocarcinoma, 1R01CA234629-01, NIH/NCI, PI – Zhang, 2/1/2019-1/31/2024, $1,143,750 ($228,750/year)

Pending

Advisor, Targeting Immune Checkpoint Protein B7-H3 (CD276) in AML Using Novel Monoclonal Antibodies, Leukemia Research Foundation, PI – Battula, 7/1/2019-6/30/2020, $100,000 ($100,000/year)

Consultant, Targeting Immune Checkpoint protein B7-H3 (CD276) in Acute Myeloid Leukemia, TRP-18045-19, Leukemia and Lymphoma Society, PI – Battula, 7/1/2019-6/30/2022, $540,054 ($180,018/year)

Other Significant Contributor, Delineating Biomarker and Therapeutic Targets for Response and Toxicity to Immune Checkpoint Blockade, 1R01CA242327-01, NIH/NCI, PI – Wargo, 7/1/2019-6/30/2024, $2,500,000 ($500,000/year)

Primary Mentor, Effect of anti-CTLA-4 and anti-PD-1 on the Differentiation of Memory Precursor T-cells and Long-term, 1K99CA241116-01, NIH/NCI, PI – Mok, 7/1/2019-6/30/2024, $646,460 ($129,292/year)

Co-Mentor, Macrophage Reprogramming and its Therapeutic Potential in Glioblastoma, 1K99CA234231-01A1, NIH/NCI, PI – Chen, 7/1/2019-6/30/2024, $660,210 ($95,682/year)

Other Significant Contributor, Therapeutic Modulation of the Innate Immune System in GBM, 1R35CA242441-01, NIH/NCI, PI – Heimberger, 7/1/2019-6/30/2026, $3,499,088 ($499,870/year)

Other Significant Contributor, Substance P Receptor Antagonist Alone and in Synergism with Check Point Inhibitors as Novel Treatment Strategies for Melanoma, Department of Defense (DOD), PI – Robinson, 9/1/2019-8/31/2021, $400,000 ($197,470/year)

Collaborator, 0.24 months, Modulating Immune Inhibitory Checkpoint LILRB2 to Enhance Anti-Tumor Immunity, 1R01CA244992-01, NIH/NCI, PI – Ajan/Sharma/Wang, 9/1/2019-8/31/2024, $2,475,956 ($492,239/year)

Other Significant Contributor, Stinging the Glioma Immune Landscape, 1R01CA237418-01A1, NIH/NCI, PI – Heimberger, 4/1/2020-3/31/2025, $1,311,882 ($251,680/year)

Other

N/A

Completed

Principal Investigator, 0.12 months, Training Program in Cancer Immunobiology, 5T32CA009598-25, NIH/NCI, 8/1/2010-10/31/2015, $1,984,164 ($424,245/year)

Principal Investigator, 2.4 months, Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy, SU2C-AACR-DT-10-12, American Association for Cancer Research (AACR), 3/1/2013-2/28/2018, $2,622,226 ($1,195,245/year)

Co-Investigator, 0.12 months, Exploring the Functional Connection Between Stromal Myofibroblasts and Tumor Immunity in PDAC to Unravel New Therapy Targets, 00001996, Lustgarten Foundation for Pancreatic Cancer Research, PI – Kalluri, 1/1/2014-5/31/2016 ($150,000/year)

Core Leader, 0.5 months, The Intersection of Epigenetic and Immune Checkpoint Therapy, SU2C-AACR-PS01, American Association for Cancer Research (AACR), 7/1/2014-4/30/2015 ($40,000/year)

Co-Investigator, 0.6 months, Function of Fibroblasts and Collagen I in Pancreas Cancer, RP150231, Cancer Prevention & Research Institute of Texas (CPRIT), PI – Kalluri, 3/1/2015-8/31/2018, $853,872 ($404,455/year)

Co-Investigator, 0.12 months, SU2C – Google [X] Immuno-Oncology Discovery Initiative, Entertainment Industry Information, PI – Sharma, 7/2/2015-7/1/2016 ($99,734/year)

Co-Mentor, MDSC-Tumor Crosstalk in Prostate Cancer Progression and Castration Resistance, 5K99CA194289-02, NIH/NCI, PI – Wang, 4/1/2016-3/31/2018, $193,416 ($96,708/year)

Co-Sponsor, Memory Potential, Molecular Characterization, and Translational Applications of the Novel ThEO/TcEO T Cell Phenotype, 5F99CA212447-02, NIH/NCI, PI – Bartkowiak, 9/22/2016-12/16/2017, $76,320 ($37,644/year)

Co-Investigator, 0.24 months, Translational Cancer Immune Monitoring Analysis Center (TCIMAC), 5U24CA224285-02, NIH/NCI, PI – Bernatchez/Mittendorf/Wistuba, 9/30/2017-3/31/2019, $6,878,270 ($1,375,654/year)

Not Funded

N/A

Patents and Technology Licenses

Patents

The Regents of the University of California, Allison JP, Leach DR, Krummel MF. Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling, United States, US5811097 A, 9/22/1998, Issued

The Regents of the University of California, Allison JP, Leach DR, Krummel MF. Blockade of Lymphocyte Down-Regulation Associated with CTLA-4 Signaling, United States, US5855887 A, 1/5/1999, Issued

The Regents of the University of California, Office of Technology Transfer, Allison JP, Leach DR, Krummel MF. Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling, United States, US6051227 A, 4/18/2000, Issued

Allison JP, Fasso M, Shastri N, SPAS-1 Cancer Antigen, United States, US20020150588 A1, 10/17/2002, Issued

Allison JP, Murphy KP, Watanabe N, Murphy TL, Yang J, Zang X, Compositions and Methods for Modulating Lymphocyte Activity, United States, US20040175380 A1, 9/9/2004, Issued

The Regents of the University of California, Allison JP, Elsas A, Hurwitz A. Stimulation of T Cells Against Self Antigens Using CTLA-4 Blocking Agents, United States, US20060034844 A1, 2/16/2006, Issued

The Regents of the University of California, Office of Technology Transfer, Allison JP, Leach DR, Krummel ME. Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling, United States, US7229628 B1, 6/12/2007, Issued

The Regents of the University of California, Allison JP, Fasso M, Shastri N. Diagnosis of Prostate Cancer with SPAS-1 Cancer Antigen, United States, US7704701 B2, 4/27/2010, Issued

Biosante Pharmaceuticals, Inc., The Regents of the University Of California, Simmons A, Jooss K, Allison J. Cancer Immunotherapy Compositions and Methods of Use, United States, US7919079 B2, 4/5/2011, Issued

Icahn School of Medicine At Mount Sinai, Memorial Sloan Kettering Cancer Center (MSKCC), Palese P, Garcia-Sastre A, Zamarin D, Allison J, Wolchok JD. Newcastle Disease Viruses and Uses Thereof, United States, US20160015760 A1, 6/21/2016, Issued

Board of Regents, The University of Texas System, Memorial Sloan-Kettering Cancer Center, Allison J, Sharma P, Quezada SA, Fu T. Combination Immunotherapy for the Treatment of Cancer, United States, US9375475 B2, 6/28/2016, Issued

Albert Einstein College of Medicine, Inc., Sloan-Kettering Institute For Cancer Research, Zang X, Allison JP. Antibodies to Human B7X for Treatment of Metastatic Cancer, United States, US9447186 B2, 9/20/2016, Issued

The Regents of the University of California, Allison J, Curran M. Methods and Compositions for Localized Secretion of Anti-CTLA-4 Antibodies, United States, US 9,868,961 B2, 1/16/2018, Issued

The Regents of the University of California, Allison JP, Van Elsas A, Hurwitz AA. Stimulation of T Cells Against Self- Antigens Using CTLA-4 Blocking Agents, United States, US20090269353 A1, 10/29/2009, Pending

Allison JP, Allison JP, Curran M. Multi-Antigen Immunotherapy for Melanoma and Prostate Cancer, United States, Pending, Pending

Allison JP, Allison JP, Murphy K, Zang X. Novel Lymphocyte Receptor of B7X Protein, United States, Pending, Pending

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

Fellowship Committee, Cancer Research Institute (CRI), Grant Reviewer, 2015

Review Committee, Cancer Prevention & Research Institute of Texas, Grant Reviewer, 2015

PUBLICATIONS

Peer-Reviewed Original Research Articles

  1. Allison JP, Mandy WJ, Kitto GB. The substrate specificity of L-asparaginase from Alcaligenes eutrophus. FEBS Lett 14(2):107-8, 4/1971. PMID: 11945731.
  2. Allison JP, Davidson L, Gutierrez-Hartman A, Kitto GB. Insolubilization of L-asparaginase by covalent attachment to nylon tubing. Biochem Biophys Res Commun 47(1):66-73, 4/1972. PMID: 5027141.
  3. Prager MD, Ludden CM, Mandy WJ, Allison JP, Kitto GB. Endotoxin-stimulated immune response to modified lymphoma cells. J Natl Cancer Inst 54(3):773-5, 3/1975. PMID: 1168264.
  4. Callahan GN, Ferrone S, Allison JP, Reisfeld RA. Detection of H-2 antigens in serum. Transplantation 20(5):431-3, 11/1975. PMID: 174256.
  5. Reisfeld RA, Allison JP, Ferrone S, Pellegrino MA, Poulik MD. HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. Transplant Proc 8(2):173-8, 6/1976. PMID: 59439.
  6. Ferrone S, Pellegrino MA, Allison JP, Reisfeld RA. Biological and chemical aspects of histocompatibility antigens in serum. Haematologica 61(4):397-417, 12/1976. PMID: 828605.
  7. Ferrone S, Mittal KK, Pellegrino MA, Allison JP, Reisfeld RA. Immunogenicity of HLA antigens purified from serum. Transplantation 23(1):7-15, 1/1977. PMID: 65035.
  8. Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA. Biologic and chemical characterization of HLA antigens in human serum. J Immunol 118(3):1004-9, 3/1977. PMID: 191523.
  9. Allison JP, Ferrone S, Pellegrino MA, Reisfeld RA. Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. Transplant Proc 9(1):601-4, 3/1977. PMID: 194373.
  10. Allison JP, Pellegrino MA, Reisfeld RA, Ferrone S. An immune adsorption technique for analysis of antigenic determinants reacting with HLA antisera. Transplant Proc 9(4):1691-3, 12/1977. PMID: 74875.
  11. Callahan GN, Allison JP. H-2 antigens on a murine lymphoma are associated with additional proteins. Nature 271(5641):165-7, 1/1978. PMID: 74802.
  12. Allison JP, Walker LE, Russell WA, Pellegrino MA, Ferrone S, Reisfeld RA, Frelinger JA, Silver J. Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A 75(8):3953-6, 8/1978. PMCID: PMC392907.
  13. Allison JP, Belvedere M, Reisfeld RA, Pellegrino MA, Ferrone S. Serologic and immunochemical characterization of HLA-A9 xenoantisera. J Immunol 121(2):579-85, 8/1978. PMID: 681750.
  14. Allison JP, Ferrone S, Walker LE, Pellegrino MA, Silver J, Reisfeld RA. Partial amino acid sequence of HLA-A9 antigen purified with a specific xenoantiserum. Transplantation 26(6):451-4, 12/1978. PMID: 569916.
  15. Callahan GN, Pellegrino MA, McCabe RP, Frugis L, Allison JP, Ferrone S. Histocompatibility antigens on tumor cells: spatial and structural relationships with tumor-associated antigens. Behring Inst Mitt 62:115-28, 1978.
  16. Callahan GN, Allison JP, Pellegrino MA, Reisfeld RA. Physical association of histocompatibility antigens and tumor-associated antigens on the surface of murine lymphoma cells. J Immunol 122(1):70-4, 1/1979. PMID: 762424.
  17. Glenney JR, Allison JP, Hixson DC, Walborg EF. Resolution and partial characterization of the major plasma membrane sialoglycoproteins of Novikoff tumor cells. J Biol Chem 254(18):9247-53, 9/1979. PMID: 479193.
  18. LeGrue SJ, Allison JP, Macek CM, Pellis NR, Kahan BD. Immunobiological properties of 1-butanol-extracted cell surface antigens. Cancer Res 41(10):3956-60, 10/1981. PMID: 7026027.
  19. Kline K, Allison JP, Sanders BG. Chemical and immunological characterization of developmentally expressed chicken erythroid surface membrane antigens. Dev Biol 91(2):389-96, 6/1982. PMID: 6178635.
  20. Nelson CH, Allison JP, Kline K, Sanders BG. Chicken fetal and adult antigen expression on erythroleukemia cells before and after induced differentiation. Cancer Res 42(11):4625-30, 11/1982. PMID: 7127300.
  21. Sanders BG, Allison JP, Kline K. Monoclonal antibody to chicken fetal antigens on normal erythroid cells and hematopoietic-lymphoid tumor cell lines. Cancer Res 42(11):4532-9, 11/1982. PMID: 6751524.
  22. Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol 129(5):2293-300, 11/1982. PMID: 6181166.
  23. Callahan GN, Pardi D, Giedlin MA, Allison JP, Morizot DM, Martin WJ. Biochemical evidence for expression of a semi-allogeneic, H-2 antigen by a murine adenocarcinoma. J Immunol 130(1):471-9, 1/1983. PMID: 6847892.
  24. Hixson DC, Allison JP, Chesner JE, Leger MJ, Ridge LL, Walborg EF. Characterization of a family of glycoproteins associated with the bile canalicular membrane of normal hepatocytes but not expressed by two transplantable rat hepatocellular carcinomas. Cancer Res 43(8):3874-84, 8/1983. PMID: 6344992.
  25. McIntyre BW, Allison JP. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell 34(3):739-46, 10/1983. PMID: 6194888.
  26. Kappler J, Kubo R, Haskins K, Hannum C, Marrack P, Pigeon M, McIntyre B, Allison J, Trowbridge I. The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. Cell 35(1):295-302, 11/1983. PMID: 6605199.
  27. Lanier LL, Richie ER, Howell AL, Allison JP. Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma. Immunogenetics 17(6):655-9, 1983. PMID: 6602763.
  28. Howell AL, Richie ER, Dennison DK, Chan JYH, Allison JP. Individual AKR lymphomas differ in expression of lymphocyte differentiation antigens and terminal deoxynucleotidyl transferase. Disease Markers 1:3-18, 1983.
  29. Hixson DC, Allison JP, McEntire KD, Nairn RS, Chesner JE, Walborg EF. Structural differences in envelope glycoproteins associated with rat leukaemia virus produced by Novikoff hepatocellular carcinoma and spontaneously transformed Wistar rat embryo cells. J Gen Virol 65 (Pt 4):743-60, 4/1984. PMID: 6368746.
  30. Hixson DC, DeLourdes Ponce M, Allison JP, Walborg EF. Cell surface expression by adult rat hepatocytes of a non-collagen glycoprotein present in rat liver biomatrix. Exp Cell Res 152(2):402-14, 6/1984. PMID: 6723795.
  31. Kline K, Allison JP, McIntyre BW, Sanders BG. Immunochemical characterization of differentiation and age-related cell surface antigens expressed by chicken erythrocytes. Cancer Res 44(8):3576-83, 8/1984. PMID: 6378372.
  32. McIntyre BW, Allison JP. Biosynthesis and processing of murine T-cell antigen receptor. Cell 38(3):659-65, 10/1984. PMID: 6488315.
  33. Pellegrino MA, Russo C, Allison JP. HLA antigens in serum. Methods Enzymol 108:614-24, 1984. PMID: 6527659.
  34. Allison JP, Lanier LL. Identification of antigen receptor-associated structures on murine T cells. Nature 314(6006):107-9, Mar 7-13, 3/1985. PMID: 2579338.
  35. Walborg EF, Tsuchida S, Weeden DS, Thomas MW, Barrick A, McEntire KD, Allison JP, Hixson DC. Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. Exp Cell Res 158(2):509-18, 6/1985. PMID: 3891389.
  36. Hixson DC, Allison JP. Monoclonal antibodies recognizing oval cells induced in the liver of rats by N-2-fluorenylacetamide or ethionine in a choline-deficient diet. Cancer Res 45(8):3750-60, 8/1985. PMID: 2410100.
  37. Allison JP, McIntyre BW, Ridge LL, Gross-Pelose J, Lanier LL. Molecular characterization of the murine T cell antigen receptor and associated structures. Fed Proc 44(13):2870-3, 10/1985. PMID: 2412897.
  38. Allison JP, McIntyre BW, Richie ER. Correlation of antigen receptor expression and surface phenotype of murine lymphomas. Federation Proc 44:2222, 1985.
  39. Saunders PH, McIntyre BW, Lawlor DA, Bridges WJ, Allison JP. The congenic mutant B6.C-H-2bm-1 (H-2bm-1) serological response to the T-cell receptor on EL4. Cell Immunol 101(2):586-92, 9/1986. PMID: 3757049.
  40. Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. J Immunol 137(8):2501-7, 10/1986. PMID: 3531334.
  41. Lanier LL, Ruitenberg JJ, Allison JP, Weiss A. Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies. J Immunol 137(7):2286-92, 10/1986. PMID: 2428866.
  42. Nagasawa R, Gross J, Kanagawa O, Townsend K, Lanier LL, Chiller J, Allison JP. Identification of a novel T cell surface disulfide-bonded dimer distinct from the alpha/beta antigen receptor. J Immunol 138(3):815-24, 2/1987. PMID: 2433330.
  43. O’Neill HC, McGrath MS, Allison JP, Weissman IL. A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. Cell 49(1):143-51, 4/1987. PMID: 2435413.
  44. Lanier LL, Federspiel NA, Ruitenberg JJ, Phillips JH, Allison JP, Littman D, Weiss A. The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. J Exp Med 165(4):1076-94, 4/1987. PMCID: PMC2188591.
  45. Kuziel WA, Takashima A, Bonyhadi M, Bergstresser PR, Allison JP, Tigelaar RE, Tucker PW. Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells. Nature 328(6127):263-6, Jul 16-22, 7/1987. PMID: 2885757.
  46. Havran WL, Poenie M, Kimura J, Tsien R, Weiss A, Allison JP. Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature 330(6144):170-3, Nov 12-18, 11/1987. PMID: 2959867.
  47. Bonyhadi M, Weiss A, Tucker PW, Tigelaar RE, Allison JP. Delta is the Cx-gene product in the gamma/delta antigen receptor of dendritic epidermal cells. Nature 330(6148):574-6, Dec 10-16, 12/1987. PMID: 3500417.
  48. Crispe IN, Shimonkevitz RP, Husmann LA, Kimura J, Allison JP. Expression of T cell antigen receptor beta-chains on subsets of mouse thymocytes. Analysis by three-color flow cytometry. J Immunol 139(11):3585-9, 12/1987. PMID: 2960738.
  49. Richie ER, McEntire B, Crispe N, Kimura J, Lanier LL, Allison JP. Alpha/beta T-cell antigen receptor gene and protein expression occurs at early stages of thymocyte differentiation. Proc Natl Acad Sci U S A 85(4):1174-8, 2/1988. PMCID: PMC279729.
  50. Richie ER, McEntire B, Phillips J, Allison JP. Altered expression of lymphocyte differentiation antigens on phorbol ester-activated CD4+8+ T cells. J Immunol 140(12):4115-22, 6/1988. PMID: 3259607.
  51. Havran WL, Allison JP. Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature 335(6189):443-5, 9/1988. PMID: 2458531.
  52. Asarnow DM, Kuziel WA, Bonyhadi M, Tigelaar RE, Tucker PW, Allison JP. Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell 55(5):837-47, 12/1988. PMID: 2847872.
  53. Allison JP, Havran WL, Asarnow D, Tigelaar RE, Tucker PW, Bonyhadi M. Gamma delta antigen receptors of Thy-1+ dendritic epidermal cells: implications for thymic differentiation. Immunol Res 7(4):292-302, 1988. PMID: 2906352.
  54. Marusic-Galesic S, Saito T, Tentori L, Zuñiga-Pflucker J, Raulet DH, Allison JP, Kruisbeek AM. A novel gamma delta T cell receptor for antigen adds limited diversity to the gamma delta repertoire in adult thymus. J Immunol 142(1):28-34, 1/1989. PMID: 2521236.
  55. Havran WL, Poenie M, Tigelaar RE, Tsien RY, Allison JP. Phenotypic and functional analysis of gamma delta T cell receptor-positive murine dendritic epidermal clones. J Immunol 142(5):1422-8, 3/1989. PMID: 2783942.
  56. Kyewski BA, Schirrmacher V, Allison JP. Antibodies against the T cell receptor/CD3 complex interfere with distinct intra-thymic cell-cell interactions in vivo: correlation with arrest of T cell differentiation. Eur J Immunol 19(5):857-63, 5/1989. PMID: 2525475.
  57. Duplay P, Lancki D, Allison JP. Distribution and ontogeny of CD2 expression by murine T cells. J Immunol 142(9):2998-3005, 5/1989. PMID: 2565352.
  58. Havran WL, Grell S, Duwe G, Kimura J, Wilson A, Kruisbeek AM, O’Brien RL, Born W, Tigelaar RE, Allison JP. Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody. Proc Natl Acad Sci U S A 86(11):4185-9, 6/1989. PMCID: PMC287415.
  59. Strober S, Dejbachsh-Jones S, Van Vlasselaer P, Duwe G, Salimi S, Allison JP. Cloned natural suppressor cell lines express the CD3+CD4-CD8- surface phenotype and the alpha, beta heterodimer of the T cell antigen receptor. J Immunol 143(4):1118-22, 8/1989. PMID: 2526181.
  60. Asarnow DM, Goodman T, LeFrancois L, Allison JP. Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature 341(6237):60-2, 9/1989. PMID: 2528075.
  61. Nairn RS, McIntyre BW, Richie ER, Allison JP. Characterization of env gene recombination in x-ray–induced thymomas of C57BL/6 mice. Mol Carcinog 2(3):126-30, 1989. PMID: 2675902.
  62. Groghan TW, Davignon JL, Evans J, Allison JP, Eisenberg RA, Frelinger JA, Cohen PL. Diminished expression of the T cell receptor on the expanded lymphocyte population in MRL/Mp-lpr/lpr mice. Autoimmunity 2(2):97-111, 1989. PMID: 2562377.
  63. Havran WL, Allison JP. Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. Nature 344(6261):68-70, 3/1990. PMID: 1968230.
  64. Gross JA, St John T, Allison JP. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol 144(8):3201-10, 4/1990. PMID: 2157764.
  65. Riegel JS, Richie ER, Allison JP. Nuclear events after activation of CD4+8+ thymocytes. J Immunol 144(9):3611-8, 5/1990. PMID: 1970353.
  66. Ferrick DA, Chan A, Rahemtulla A, Widacki SM, Xia M, Broughton H, Gajewski DA, Ballhausen W, Allison JP, Bluestone JA. Expression of a T cell receptor gamma-chain (V gamma 1.1J gamma 4C gamma 4) transgene in mice influences T cell receptor ontogeny and thymic architecture during development. J Immunol 145(1):20-7, 7/1990. PMID: 2141615.
  67. Mitchell DL, Allison JP, Nairn RS. Immunoprecipitation of pyrimidine(6-4)pyrimidone photoproducts and cyclobutane pyrimidine dimers in uv-irradiated DNA. Radiat Res 123(3):299-303, 9/1990. PMID: 2217727.
  68. Lotscher E, Allison JP. Nucleotide and deduced amino acid sequence of a murine cDNA clone encoding one member of the hsp65 multigene family. Nucleic Acids Res 18(23):7153, 12/1990. PMCID: PMC332799.
  69. Glaichenhaus N, Davis C, Bornschlegel K, Allison JP, Shastri N. A novel strategy for the generation of T cell lines lacking expression of endogenous alpha- and/or beta-chain T cell receptor genes. J Immunol 146(7):2095-101, 4/1991. PMID: 1826016.
  70. Iwashima M, Green A, Bonyhadi M, Davis MM, Allison JP, Chien YH. Expression of a fetal gamma delta T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. Int Immunol 3(4):385-93, 4/1991. PMID: 1831656.
  71. Havran WL, Chien YH, Allison JP. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science 252(5011):1430-2, 6/1991. PMID: 1828619.
  72. Nandi D, Allison JP. Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol 147(6):1773-8, 9/1991. PMID: 1679835.
  73. Allison JP, Havran WL. The immunobiology of T cells with invariant gamma delta antigen receptors. Annu Rev Immunol 9:679-705, 1991. PMID: 1832874.
  74. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356(6370):607-9, 4/1992. PMID: 1313950.
  75. Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 149(2):380-8, 7/1992. PMID: 1320641.
  76. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259(5093):368-70, 1/1993. PMID: 7678351.
  77. Gramzinski RA, Adams E, Gross JA, Goodman TG, Allison JP, Lefrançois L. T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. Int Immunol 5(2):145-53, 2/1993. PMID: 8383994.
  78. Wells FB, Tatsumi Y, Bluestone JA, Hedrick SM, Allison JP, Matis LA. Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. J Exp Med 177(4):1061-70, 4/1993. PMCID: PMC2190965.
  79. Harding FA, Allison JP. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 177(6):1791-6, 6/1993. PMCID: PMC2191062.
  80. Giese T, Allison JP, Davidson WF. Functionally anergic lpr and gld B220+ T cell receptor (TCR)-alpha/beta+ double-negative T cells express CD28 and respond to costimulation with phorbol myristate acetate and antibodies to CD28 and the TCR. J Immunol 151(2):597-609, 7/1993. PMID: 7687618.
  81. Leclercq G, Plum J, Nandi D, De Smedt M, Allison JP. Intrathymic differentiation of V gamma 3 T cells. J Exp Med 178(1):309-15, 7/1993. PMCID: PMC2191082.
  82. Page DM, Kane LP, Allison JP, Hedrick SM. Two signals are required for negative selection of CD4+CD8+ thymocytes. J Immunol 151(4):1868-80, 8/1993. PMID: 7688388.
  83. Sagerström CG, Kerr EM, Allison JP, Davis MM. Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A 90(19):8987-91, 10/1993. PMCID: PMC47486.
  84. Nandi D, Allison JP. Characterization of neutrophils and T lymphocytes associated with the murine vaginal epithelium. Reg Immunol 5(6):332-8, Nov-Dec, 11/1993. PMID: 8068536.
  85. Clements JL, Winslow G, Donahue C, Cooper SM, Allison JP, Budd RC. Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. Int Immunol 5(11):1451-60, 11/1993. PMID: 7903158.
  86. Holsti MA, McArthur J, Allison JP, Raulet DH. Role of IL-6, IL-1, and CD28 signaling in responses of mouse CD4+ T cells to immobilized anti-TCR monoclonal antibody. J Immunol 152(4):1618-28, 2/1994. PMID: 7907103.
  87. Nandi D, Gross JA, Allison JP. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol 152(7):3361-9, 4/1994. PMID: 7511644.
  88. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54(24):6477-83, 12/1994. PMID: 7527298.
  89. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459-65, 8/1995. PMCID: PMC2192127.
  90. Zhang Y, Cado D, Asarnow DM, Komori T, Alt FW, Raulet DH, Allison JP. The role of short homology repeats and TdT in generation of the invariant gamma delta antigen receptor repertoire in the fetal thymus. Immunity 3(4):439-47, 10/1995. PMID: 7584135.
  91. Liu B, Podack ER, Allison JP, Malek TR. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 156(3):1117-25, 2/1996. PMID: 8557987.
  92. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734-6, 3/1996. PMID: 8596936.
  93. Krummel MF, Sullivan TJ, Allison JP. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol 8(4):519-23, 4/1996. PMID: 8671638.
  94. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183(6):2533-40, 6/1996. PMCID: PMC2192613.
  95. Chambers CA, Allison JP. The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction. Eur J Immunol 26(12):3224-9, 12/1996. PMID: 8977326.
  96. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 73(1-2):57-62, 3/1997. PMID: 9058759.
  97. Fournier S, Rathmell JC, Goodnow CC, Allison JP. T cell-mediated elimination of B7.2 transgenic B cells. Immunity 6(3):327-39, 3/1997. PMID: 9075933.
  98. Liao XC, Fournier S, Killeen N, Weiss A, Allison JP, Littman DR. Itk negatively regulates induction of T cell proliferation by CD28 costimulation. J Exp Med 186(2):221-8, 7/1997. PMCID: PMC2198978.
  99. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 94(15):8099-103, 7/1997. PMCID: PMC21563.
  100. Zhang Y, Allison JP. Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci U S A 94(17):9273-8, 8/1997. PMCID: PMC23153.
  101. Chambers CA, Cado D, Truong T, Allison JP. Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci U S A 94(17):9296-301, 8/1997. PMCID: PMC23164.
  102. Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol 159(7):3460-73, 10/1997. PMID: 9317145.
  103. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7(6):885-95, 12/1997. PMID: 9430233.
  104. Lühder F, Höglund P, Allison JP, Benoist C, Mathis D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 187(3):427-32, 2/1998. PMCID: PMC2212113.
  105. Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int J Cancer 77(1):107-13, 7/1998. PMID: 9639401.
  106. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 95(17):10067-71, 8/1998. PMCID: PMC21462.
  107. Rathmell JC, Fournier S, Weintraub BC, Allison JP, Goodnow CC. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. J Exp Med 188(4):651-9, 8/1998. PMCID: PMC2213352.
  108. Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol 28(10):3137-43, 10/1998. PMID: 9808182.
  109. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 162(10):5813-20, 5/1999. PMID: 10229815.
  110. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A 96(15):8603-8, 7/1999. PMCID: PMC17563.
  111. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3):355-66, 8/1999. PMCID: PMC2195583.
  112. Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 96(20):11476-81, 9/1999. PMCID: PMC18058.
  113. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 96(26):15074-9, 12/1999. PMCID: PMC24775.
  114. Chambers CA, Allison JP. CTLA-4–the costimulatory molecule that doesn’t: regulation of T-cell responses by inhibition. Cold Spring Harb Symp Quant Biol 64:303-12, 1999. PMID: 11232300.
  115. Piganelli JD, Poulin M, Martin T, Allison JP, Haskins K. Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse. J Autoimmun 14(2):123-31, 3/2000. PMID: 10677243.
  116. Yu X, Fournier S, Allison JP, Sharpe AH, Hodes RJ. The role of B7 costimulation in CD4/CD8 T cell homeostasis. J Immunol 164(7):3543-53, 4/2000. PMID: 10725709.
  117. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60(9):2444-8, 5/2000. PMID: 10811122.
  118. Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A 97(22):12204-9, 10/2000. PMCID: PMC17319.
  119. Kuhns MS, Epshteyn V, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci U S A 97(23):12711-6, 11/2000. PMCID: PMC18829.
  120. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409(6816):97-101, 1/2001. PMID: 11343121.
  121. Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, Metzler B, Chambers CA, Allison JP. Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. Proc Natl Acad Sci U S A 98(5):2587-92, 2/2001. e-Pub 2/2001. PMCID: PMC30182.
  122. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194(4):481-9, 8/2001. PMCID: PMC2193490.
  123. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194(6):823-32, 9/2001. PMCID: PMC2195955.
  124. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16(1):23-35, 1/2002. PMID: 11825563.
  125. Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci U S A 99(5):3013-7, 3/2002. e-Pub 2/2002. PMCID: PMC122464.
  126. Chambers CA, Kang J, Wu Y, Held W, Raulet DH, Allison JP. The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. Blood 99(12):4509-16, 6/2002. PMID: 12036882.
  127. Prilliman KR, Lemmens EE, Palioungas G, Wolfe TG, Allison JP, Sharpe AH, Schoenberger SP. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. J Immunol 169(8):4094-7, 10/2002. PMID: 12370335.
  128. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100(8):4712-7, 4/2003. e-Pub 4/2003. PMCID: PMC153621.
  129. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 100(9):5336-41, 4/2003. e-Pub 4/2003. PMCID: PMC154346.
  130. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4(7):670-9, 7/2003. e-Pub 6/2003. PMID: 12796776.
  131. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100(14):8372-7, 7/2003. e-Pub 6/2003. PMCID: PMC166236.
  132. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 100(18):10388-92, 9/2003. e-Pub 8/2003. PMCID: PMC193571.
  133. Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol 172(1):34-9, 1/2004. PMID: 14688306.
  134. Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22(13-14):1700-8, 4/2004. PMID: 15068853.
  135. Mamura M, Lee W, Sullivan TJ, Felici A, Sowers AL, Allison JP, Letterio JJ. CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. Blood 103(12):4594-601, 6/2004. e-Pub 3/2004. PMID: 15016653.
  136. Stohl W, Xu D, Kim KS, David CS, Allison JP. MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol 16(7):895-904, 7/2004. e-Pub 5/2004. PMID: 15136557.
  137. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21(3):401-13, 9/2004. PMID: 15357951.
  138. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 173(10):6098-108, 11/2004. PMID: 15528346.
  139. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11(2 Pt 1):728-34, 1/2005. PMID: 15701862.
  140. Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol 174(4):1922-31, 2/2005. PMID: 15699119.
  141. Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. 1982. J Immunol 174(3):1144-51, 2/2005. PMID: 15661866.
  142. Loke P, Zang X, Hsuan L, Waitz R, Locksley RM, Allen JE, Allison JP. Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. Proc Natl Acad Sci U S A 102(28):9872-7, 7/2005. e-Pub 7/2005. PMCID: PMC1175004.
  143. Williams JA, Hathcock KS, Klug D, Harada Y, Choudhury B, Allison JP, Abe R, Hodes RJ. Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint. J Immunol 175(7):4199-207, 10/2005. PMCID: PMC1343453.
  144. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682-7, 2/2006. e-Pub 12/2005. PMID: 16382236.
  145. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116(7):1935-45, 7/2006. e-Pub 6/2006. PMCID: PMC1479425.
  146. Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol 177(2):1052-61, 7/2006. PMID: 16818761.
  147. Zang X, Loke P, Kim J, Wojnoonski K, Kusdra L, Allison JP. A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics 88(6):841-845, 12/2006. e-Pub 10/2006. PMID: 17014982.
  148. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13(6):1810-5, 3/2007. PMID: 17363537.
  149. Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD, Lary JW, Cole JL, Deng H, Xiao H, Dilorenzo TP, Allison JP, Nathenson SG, Almo SC. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity 26(3):311-21, 3/2007. PMID: 17363302.
  150. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13(7):2158-67, 4/2007. PMID: 17404100.
  151. Enzler T, Gillessen S, Dougan M, Allison JP, Neuberg D, Oble DA, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood 110(3):954-61, 8/2007. e-Pub 5/2007. PMCID: PMC1924767.
  152. Loke P, Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M, Allison JP, Allen JE. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol 179(6):3926-36, 9/2007. PMID: 17785830.
  153. Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A 104(45):17765-70, 11/2007. e-Pub 10/2007. PMCID: PMC2077030.
  154. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 104(49):19458-63, 12/2007. e-Pub 11/2007. PMCID: PMC2148311.
  155. Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, Jungbluth AA, Allison JP. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 319(5860):215-20, 1/2008. PMID: 18187659.
  156. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res 68(3):889-92, 2/2008. PMID: 18245491.
  157. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105(8):3005-10, 2/2008. e-Pub 2/2008. PMCID: PMC2268575.
  158. Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A 105(9):3509-14, 3/2008. e-Pub 2/2008. PMCID: PMC2265147.
  159. Kavanagh B, O’Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112(4):1175-83, 8/2008. e-Pub 6/2008. PMCID: PMC2515138.
  160. Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother 57(8):1263-70, 8/2008. e-Pub 1/2008. PMID: 18236040.
  161. Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 68(15):6054-8, 8/2008. PMCID: PMC2918370.
  162. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 205(9):2125-38, 9/2008. e-Pub 8/2008. PMCID: PMC2526206.
  163. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 105(51):20410-5, 12/2008. e-Pub 12/2008. PMCID: PMC2629307.
  164. Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy 1(1):129-39, 1/2009. PMCID: PMC2864044.
  165. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206(8):1717-25, 8/2009. e-Pub 7/2009. PMCID: PMC2722174.
  166. Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 69(19):7747-55, 10/2009. e-Pub 9/2009. PMCID: PMC2756314.
  167. Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 11(7):912-22, 2009. PMCID: PMC2932850.
  168. Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, Old LJ, Wolchok JD. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 10:1, 1/2010. e-Pub 1/2010. PMCID: PMC2964016.
  169. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107(9):4275-80, 3/2010. e-Pub 2/2010. PMCID: PMC2840093.
  170. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207(3):637-50, 3/2010. e-Pub 2/2010. PMCID: PMC2839156.
  171. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116(7):1767-75, 4/2010. PMCID: PMC2917065.
  172. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 5/2010. e-Pub 5/2010. PMCID: PMC2919850.
  173. Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16(10):2781-91, 5/2010. e-Pub 5/2010. PMID: 20460483.
  174. Gottschalk RA, Corse E, Allison JP. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med 207(8):1701-11, 8/2010. e-Pub 7/2010. PMCID: PMC2916126.
  175. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23(8):1104-12, 8/2010. e-Pub 5/2010. PMCID: PMC2976590.
  176. Corse E, Gottschalk RA, Krogsgaard M, Allison JP. Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol 8(9), 9/2010. e-Pub 9/2010. PMCID: PMC2939023.
  177. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 37(5):473-84, 10/2010. PMCID: PMC3008567.
  178. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A 108(1):266-71, 1/2011. e-Pub 12/2010. PMCID: PMC3017182.
  179. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6(4):e19499, 4/2011. e-Pub 4/2011. PMCID: PMC3085474.
  180. Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol 186(9):5039-45, 5/2011. PMID: 21505216.
  181. Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP, Li MO. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity 35(1):123-34, 7/2011. e-Pub 7/2011. PMCID: PMC3430371.
  182. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 60(8):1137-46, 8/2011. e-Pub 4/2011. PMCID: PMC3654853.
  183. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, Allison JP, DeMatteo RP. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17(9):1094-100, 8/2011. e-Pub 8/2011. PMCID: PMC3278279.
  184. Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med 208(8):1683-94, 8/2011. e-Pub 7/2011. PMCID: PMC3149222.
  185. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 108(40):16723-8, 10/2011. e-Pub 9/2011. PMCID: PMC3189057.
  186. Gottschalk RA, Hathorn MM, Beuneu H, Corse E, Dustin ML, Altan-Bonnet G, Allison JP. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc Natl Acad Sci U S A 109(3):881-6, 1/2012. e-Pub 1/2012. PMCID: PMC3271915.
  187. Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, Allison JP. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 72(2):430-9, 1/2012. e-Pub 11/2011. PMCID: PMC4526218.
  188. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385):400-4, 2/2012. e-Pub 2/2012. PMCID: PMC3874809.
  189. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol 188(3):976-80, 2/2012. e-Pub 12/2011. PMID: 22198953.
  190. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925-31, 3/2012. PMCID: PMC3345206.
  191. Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A 109(16):6187-92, 4/2012. e-Pub 4/2012. PMCID: PMC3341063.
  192. Zhang M, Ju W, Yao Z, Yu P, Wei BR, Simpson RM, Waitz R, Fassò M, Allison JP, Waldmann TA. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol 188(12):6156-64, 6/2012. e-Pub 5/2012. PMCID: PMC3370156.
  193. Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol 189(3):1123-7, 8/2012. e-Pub 7/2012. PMID: 22753941.
  194. Lee JS, Scandiuzzi L, Ray A, Wei J, Hofmeyer KA, Abadi YM, Loke P, Lin J, Yuan J, Serreze DV, Allison JP, Zang X. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol 189(8):4165-74, 10/2012. e-Pub 9/2012. PMCID: PMC3466330.
  195. Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics 9(4):827-43, 10/2012. PMCID: PMC3480576.
  196. Srivastava PK, Cerundolo V, Knuth A, Allison JP. An open invitation to the cancer immunology community. Cancer Immun 12:1, 2012. e-Pub 5/2012. PMCID: PMC3380353.
  197. Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS One 7(4):e35222, 2012. e-Pub 4/2012. PMCID: PMC3320876.
  198. Corse E, Gottschalk RA, Park JS, Sepulveda MA, Loke P, Sullivan TJ, Johnson LK, Allison JP. Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. J Immunol 190(2):526-30, 1/2013. e-Pub 12/2012. PMCID: PMC4964790.
  199. Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, Amit AS, Kang C, Geddes JE, Allison JP, Socci ND, Savage PA. Aire-dependent thymic development of tumor-associated regulatory T cells. Science 339(6124):1219-24, 3/2013. PMCID: PMC3622085.
  200. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 210(4):743-55, 4/2013. e-Pub 4/2013. PMCID: PMC3620352.
  201. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210(7):1389-402, 7/2013. e-Pub 6/2013. PMCID: PMC3698523.
  202. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695-710, 8/2013. e-Pub 7/2013. PMCID: PMC3754863.
  203. Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 1(4):235-44, 10/2013. PMCID: PMC3880021.
  204. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1(4):229-34, 10/2013. e-Pub 7/2013. PMCID: PMC4636341.
  205. Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, Allison JP, Melamed J, Jäger E, Ritter G, Old LJ, Gnjatic S. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clin Cancer Res 19(22):6112-25, 11/2013. e-Pub 9/2013. PMID: 24081977.
  206. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra32, 3/2014. PMCID: PMC4106918.
  207. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 211(4):715-25, 4/2014. e-Pub 3/2014. PMCID: PMC3978270.
  208. Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, Waldmann TA, Steel JC. Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer. Gene Ther 21(4):393-401, 4/2014. e-Pub 2/2014. PMCID: PMC3976433.
  209. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6):719-34, 6/2014. e-Pub 5/2014. PMCID: PMC4180632.
  210. Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunol Res 2(10):970-80, 10/2014. e-Pub 7/2014. PMID: 25038199.
  211. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528):577-81, 11/2014. PMCID: PMC4279952.
  212. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 25(2):208-24, 2/2015. e-Pub 1/2015. PMCID: PMC4650573.
  213. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 25(3):399-400, 3/2015. PMCID: PMC4349252.
  214. Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J Immunol 194(5):2089-98, 3/2015. e-Pub 1/2015. PMID: 25624453.
  215. Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknect E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, Mak TW, van den Brink M, Zeiser R, Blazar BR. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood 125(21):3335-46, 5/2015. e-Pub 3/2015. PMCID: PMC4440885.
  216. Kreymborg K, Haak S, Murali R, Wei J, Waitz R, Gasteiger G, Savage PA, van den Brink MR, Allison JP. Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. Cancer Immunol Res 3(8):849-54, 8/2015. e-Pub 6/2015. PMCID: PMC5939565.
  217. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-77, 8/2015. e-Pub 6/2015. PMCID: PMC4527963.
  218. Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, Wu CC, Hagos Y, Burckhardt BC, Pentcheva-Hoang T, Nischal H, Allison JP, Zeisberg M, Kalluri R. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med 21(9):998-1009, 9/2015. e-Pub 8/2015. PMCID: PMC4587560.
  219. Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A 112(38):E5290-9, 9/2015. e-Pub 9/2015. PMCID: PMC4586868.
  220. Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep 13(2):412-24, 10/2015. e-Pub 9/2015. PMCID: PMC5013825.
  221. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis induces Immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 28(6):831-3, 12/2015. e-Pub 12/2015. PMID: 28843279.
  222. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 3/2016. e-Pub 2/2016. PMCID: PMC4839346.
  223. Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP, Feldman RM. ICOS promotes the function of CD4+ effector T cells during anti-OX40-mediated tumor rejection. Cancer Res 76(13):3684-9, 7/2016. e-Pub 5/2016. PMID: 27197182.
  224. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-37, 8/2016. e-Pub 6/2016. PMCID: PMC5082984.
  225. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 7:12632, 8/2016. e-Pub 8/2016. PMCID: PMC5013604.
  226. Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun 7:12335, 8/2016. e-Pub 8/2016. PMCID: PMC4979067.
  227. Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report. J Hematol Oncol 9(1):81, 9/2016. e-Pub 9/2016. PMCID: PMC5011857.
  228. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-24, 10/2016. e-Pub 10/2016. PMCID: PMC5081579.
  229. Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris E, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, McArthur HL. Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunol Res 4(10):835-44, 10/2016. e-Pub 9/2016. PMCID: PMC5064839.
  230. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167(2):397-404.e9, 10/2016. e-Pub 9/2016. PMCID: PMC5088716.
  231. McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res 22(23):5729-37, 12/2016. e-Pub 8/2016. PMCID: PMC5161031.
  232. Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun 8:14340, 2/2017. e-Pub 2/2017. PMCID: PMC5316835.
  233. Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic melanoma patient had a complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunol Res 5(2):100-5, 2/2017. e-Pub 1/2017. PMID: 28062513.
  234. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res 77(4):839-50, 2/2017. e-Pub 11/2016. PMCID: PMC5875182.
  235. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 3/2017. PMCID: PMC5819607.
  236. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-53, 4/2017. e-Pub 2/2017. PMCID: PMC5809128.
  237. Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, Allison JP, LeBleu VS, Kalluri R. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun 8:15095, 4/2017. e-Pub 4/2017. PMCID: PMC5414182.
  238. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-5, 5/2017. e-Pub 3/2017. PMCID: PMC5466900.
  239. Nawaf MG, Ulvmar MH, Withers DR, McConnell FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP, Lane PJL. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. J Immunol 199(3):974-81, 8/2017. e-Pub 6/2017. PMCID: PMC5523579.
  240. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe’er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170(6):1120-33.e17, 9/2017. e-Pub 8/2017. PMCID: PMC5591072.
  241. Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun 8(1):451, 9/2017. e-Pub 9/2017. PMCID: PMC5587668.
  242. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov 7(10):1088-97, 10/2017. e-Pub 7/2017. PMCID: PMC5628137.
  243. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 4/2017. PMCID: PMC5557036.
  244. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35, 2017. e-Pub 4/2017. PMCID: PMC5394629.
  245. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 1/2018. e-Pub 11/2017. PMCID: PMC5827966.
  246. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-93, 2/2018. e-Pub 1/2018. PMID: 29361468.
  247. Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res 6(2):189-200, 2/2018. e-Pub 1/2018. PMID: 29339377.
  248. Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL, Vence LM, Allison JP, Gulbis AM, Sharma P. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 24(5):1011-8, 3/2018. e-Pub 12/2017. PMCID: PMC5844825.
  249. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59(4):790-802, 4/2018. e-Pub 7/2017. PMCID: PMC5872841.
  250. Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32(5):1094-105, 5/2018. e-Pub 2/2018. PMID: 29487386.
  251. Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-8, 8/2018. e-Pub 7/2018. PMCID: PMC6118570.
  252. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 11/2018. e-Pub 10/2018. PMID: 30297909.
  253. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1941, 12/2018. e-Pub 10/2018. PMID: 30361510.
  254. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804-1808, 12/2018. e-Pub 11/2018. PMCID: PMC6322556.
  255. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1942, 12/2018. e-Pub 10/2018. PMID: 30361511.
  256. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 25(1):188, 1/2019. e-Pub 11/2018. PMID: 30479380.
  257. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 116(5):1692-1697, 1/2019. e-Pub 1/2019. PMCID: PMC6358697.
  258. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ Book 39:147-164, 1/2019. e-Pub 5/2019. PMID: 31099674.
  259. Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clin Cancer Res 25(4):1233-1238, 2/2019. e-Pub 7/2018. PMCID: PMC6348141.
  260. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov 9(3):370-383, 3/2019. e-Pub 11/2018. PMCID: PMC6397669.
  261. Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe’er D, Allison JP. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity 50(4):1084-1098.e10, 4/2019. e-Pub 3/2019. PMID: 30926234.
  262. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470-1481, 5/2019. e-Pub 11/2018. PMCID: PMC6467779.
  263. Sharma N, Vacher J, Allison JP. TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. Proc Natl Acad Sci U S A 116(21):10453-10462, 5/2019. e-Pub 5/2019. PMID: 31076558.

Invited Articles

  1. Lanier LL, Serafini AT, Ruitenberg JJ, Cwirla S, Federspiel NA, Phillips JH, Allison JP, Weiss A. The gamma T-cell antigen receptor. J Clin Immunol 7(6):429-40, 11/1987. PMID: 3320076.
  2. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3(7):611-8, 7/2002. PMID: 12087419.
  3. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205-14, 4/2015. PMCID: PMC5905674.
  4. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069-1086, 9/2018. e-Pub 8/2018. PMID: 30115704.

Editorials

  1. Ferrone S, Allison JP, Pellegrino MA. Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol 7:239-81, 1978. PMID: 103685.
  2. Allison JP. Contributions of hybridoma technology to cancer immunology. The Cancer Bulletin 33:226-32, 1981.
  3. Allison JP, Ridge L, Lund J, Gross-Pelose J, Lanier L, McIntyre BW. The murine T cell antigen receptor and associated structures. Immunol Rev 81:145-60, 10/1984. PMID: 6210241.
  4. Allison JP, Lanier LL. Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol 5:503-40, 1987. PMID: 2439105.
  5. Allison JP, Lanier LL. The T-cell antigen receptor gamma gene: rearrangement and cell lineages. Immunol Today 8(10):293-6, 1987. PMID: 25290833.
  6. Allison JP, Raulet DH. The immunobiology of gamma delta+ T cells. Semin Immunol 2(1):59-65, 1/1990. PMID: 2151798.
  7. Havran WL, Carbone A, Allison JP. Murine T cells with invariant gamma delta antigen receptors: origin, repertoire, and specificity. Semin Immunol 3(2):89-97, 3/1991. PMID: 1716172.
  8. Allison JP. Gamma delta T-cell development. Curr Opin Immunol 5(2):241-6, 4/1993. PMID: 8389558.
  9. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 6(3):414-9, 6/1994. PMID: 7522466.
  10. Robey E, Allison JP. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today 16(7):306-10, 7/1995. PMID: 7576059.
  11. Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 7(5):682-6, 10/1995. PMID: 8573312.
  12. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 270(5238):932-3, 11/1995. PMID: 7481795.
  13. Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, Cassell D, Brunner M, Allison JP. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 153:27-46, 10/1996. PMID: 9010718.
  14. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 9(3):396-404, 6/1997. PMID: 9203422.
  15. Nussenzweig M, Allison JP. Lymphocyte activation and effector functions. How signals are integrated in the immune system. Curr Opin Immunol 9(3):293-5, 6/1997. PMID: 9203423.
  16. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 7(4):445-50, 10/1997. PMID: 9354465.
  17. Allison JP, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S, Brunner M, Krummel M. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found Symp 215:92-8; discussion 98-102, 186-90, 1998. PMID: 9760573.
  18. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 11(2):203-10, 4/1999. PMID: 10209159.
  19. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol Chapter 20:Unit 20.5, 11/2001. PMID: 18432778.
  20. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565-94, 2001. PMID: 11244047.
  21. Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer: advances in immunotherapy. BioDrugs 17(2):131-8, 2003. PMID: 12641491.
  22. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10(9):887-92, 9/2004. PMID: 15340404.
  23. Loke P, Allison JP. Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Res Ther 6(5):208-14, 2004. e-Pub 8/2004. PMCID: PMC546290.
  24. Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol 130(6):809-24, 9/2005. PMID: 16156851.
  25. Puré E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol 6(12):1207-10, 12/2005. PMID: 16369561.
  26. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18(2):206-13, 4/2006. e-Pub 2/2006. PMID: 16464564.
  27. Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 24(5):442-7, Sep-Oct, 9/2006. PMCID: PMC1976273.
  28. Zang X, Allison JP. To be or not to be B7. J Clin Invest 116(10):2590-3, 10/2006. PMCID: PMC1578606.
  29. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339, 2006. PMCID: PMC1951510.
  30. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncol 34(2):165-72, 4/2007. PMCID: PMC6009830.
  31. Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 12(3):192-9, 9/2007. PMID: 17785201.
  32. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13(18 Pt 1):5271-9, 9/2007. PMID: 17875755.
  33. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 224:141-65, 8/2008. PMID: 18759925.
  34. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 229(1):67-87, 5/2009. PMID: 19426215.
  35. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 157(1):9-19, 7/2009. e-Pub 2/2009. PMCID: PMC2710587.
  36. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323-37, 9/2009. PMCID: PMC5779623.
  37. Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol 22(3):326-32, 6/2010. e-Pub 1/2010. PMID: 20116985.
  38. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 241(1):104-18, 5/2011. PMCID: PMC3727276.
  39. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11(11):805-12, 10/2011. e-Pub 10/2011. PMCID: PMC3426440.
  40. Krummel MF, Allison JP. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465. J Immunol 187(7):3459-65, 10/2011. PMID: 21934097.
  41. Allison JP, Benoist C, Chervonsky AV. Nobels: Toll pioneers deserve recognition. Nature 479(7372):178, 11/2011. e-Pub 11/2011. PMID: 22071753.
  42. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O’Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med 9:214, 12/2011. e-Pub 12/2011. PMCID: PMC3338100.
  43. Sharma P, Allison JP. Retrospective. Lloyd J. Old (1933-2011). Science 335(6064):49, 1/2012. PMID: 22223799.
  44. Curran MA, Callahan MK, Subudhi SK, Allison JP. Response to “Ipilimumab (Yervoy) and the TGN1412 catastrophe”. Immunobiology 217(6):590-2, 6/2012. e-Pub 11/2011. PMID: 22459268.
  45. Waitz R, Fassò M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology 1(4):544-6, 7/2012. PMCID: PMC3382897.
  46. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O’Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D’Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10:205, 10/2012. e-Pub 10/2012. PMCID: PMC3554496.
  47. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 12:14, 2012. e-Pub 5/2012. PMCID: PMC3380347.
  48. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O’Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 1291:1-13, 7/2013. e-Pub 6/2013. PMCID: PMC3910157.
  49. Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, Brady MS, Coit DG, Allison JP, Wolchok JD, Ariyan CE. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol 20(9):3106-11, 9/2013. e-Pub 5/2013. PMID: 23681603.
  50. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2(9):831-8, 9/2014. PMCID: PMC5367158.
  51. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 65:185-202, 2014. e-Pub 10/2013. PMID: 24188664.
  52. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348(6230):56-61, 4/2015. PMID: 25838373.
  53. Allison JP. Checkpoints. Cell 162(6):1202-5, 9/2015. PMID: 26359978.
  54. Allison JP. Immune checkpoint blockade in cancer therapy: the 2015 Lasker-DeBakey Clinical Medical Research Award. JAMA 314(11):1113-4, 9/2015. PMID: 26348357.
  55. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-80, 2015. e-Pub 8/2015. PMCID: PMC4825325.
  56. Allison J, Neill US. A conversation with James Allison. J Clin Invest 126(1):3-4, 1/2016. e-Pub 1/2016. PMCID: PMC4701563.
  57. Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P. De-risking immunotherapy: report of a consensus workshop of the cancer immunotherapy consortium of the Cancer Research Institute. Cancer Immunol Res 4(4):279-88, 4/2016. PMID: 27036972.
  58. Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res 25(11):3469-3470, 6/2019. PMID: 31160495.

Other Articles

N/A

Abstracts

  1. Demaria S, Kawashima N, Devitt ML, Babb JS, Allison JP, Formenti SC. Combination of local radiation with targeted immunomodulation improves systemic tumor control. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL. 64(7 Supplement) (#2193), 4/2004.
  2. Simmons AD, Moskalenko M, Creson J, Yi S, Allison JP, Fang J, Jooss K. Local secretion of anti-CTLA4 antibody from a GM-CSF-secreting tumor cell vaccine enhances vaccine efficacy. Proceedings of the 97th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC. 66(8 Supplement) (#1520), 4/2006.
  3. Curran M, Allison J. Cellular vaccines expressing Flt3-ligand synergize with CTLA-4 blockade to reject established tumors. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (AACR), San Diego, CA. 68(9 Supplement) (#3798), 5/2008.
  4. Sharma P, Kamat A, Tang DN, Chen H, Fu T, Sun J, Troncoso P, Yuan J, Wolchok J, Quezada S, Logothetis C, Allison J. Assessing immunologic impact of anti-CTLA-4 therapy on a pre-surgical clinical trial. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research (AACR), Denver, CO. 69(9 Supplement) (#5665), 5/2009.
  5. Yuan J, Ku G, Gallardo H, Orlandi F, Manukian G, Rasalan T, Li H, Xu Y, Vyas S, Mu Z, Simpronio J, Chapman P, Panageas K, Terzulli S, Allison J, Houghton A, Wolchok J. Safety and immunogenicity of gp100 DNA vaccines in patients with melanoma. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research (AACR), Denver, CO. 69(9 Supplement) (#715), 5/2009.
  6. Ariyan CE, Quezada S, Corse E, Montalvo W, Allison J. Improved survival with gemcitabine and CTLA-4 blockade in a murine model of prostate cancer. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL. 71(8 Supplement) (#1786), 4/2011.
  7. Diab A, McArthur HL, Solomon S, Comstock C, Maybody M, Sacchini V, Durack J, Gucalp A, Yuan J, Patil S, Thorne A, Sung J, Kotin A, Morris E, Brogi E, Morrow M, Wolchok J, Allison J, Hudis C, Norton L. A pilot study of single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer scheduled for mastectomy. Thirty-Fifth Annual Cancer Therapy & Research Center (CTRC) American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium, San Antonio, TX. 72(24 Supplement) (#OT3-1-01), 12/2012.
  8. Subudhi SK, Montalvo-Ortiz W, Scher HI, Allison JP. Dissecting the therapeutic effects of anti-CTLA-4 and ADT in a murine hormone-sensitive prostate cancer. Genitourinary Cancers Symposium, Orlando, FL. (#61), 2/2013.
  9. Diab A, Solomon SB, Sacchini V, Comstock C, Maybody M, Durack JC, Sung JS, Blum B, Neville DA, Kotin A, Yuan J, Patil S, Morris EA, Brogi E, Morrow M, Wolchok JD, Hudis C, Allison J, Norton L, McArthur HL. A pilot study of preoperative, single-dose ipilimumab (Ipi) and/or cryoablation (cryo) in women (pts) with early stage/resectable breast cancer (ESBC). Proceedings of the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting, Chicago, IL. (#1098), 6/2013.
  10. Diab A, Solomon SB, Comstock C, Maybody M, Sacchini V, Durack J, Blum B, Yuan J, Patil S, Neville D, Sung J, Kotin A, Morris E, Brogi E, Morrow M, Wolchok J, Allison J, Hudis C, Norton L, McArthur H. A pilot study of pre-operative (pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (cryo) in women (pts) with early stage/resectable breast cancer (ESBC). Thirty-Sixth Annual Cancer Therapy & Research Center (CTRC) American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium, San Antonio, TX. 73(24 Supplement) (#P4-13-01), 12/2013.
  11. Zamarin D, Holmgaard RB, Subudhi SK, Park J-S, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. Proceedings of the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago, IL. (#3051), 6/2014.
  12. Page DB, Diab A, Yuan J, Dong Z, Emerson R, Robins H, Redmond D, Zhao C, Mu Z, Wong P, Solomon SB, Sacchini V, Morrow M, Brogi E, Patil S, Wolchok JD, Hudis CA, Norton L, Allison JP, McArthur HL. T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). Proceedings of the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, Chicago, IL. (#3021), 6/2014.
  13. Page DB, Yuan J, Ginsberg A, Dong Z, Wong P, Emerson R, Sung JS, Comstock C, Solomon SB, Saccini V, Morrow M, Brogi E, Morris EA, Patil S, Robins H, Wolchok JD, Hudis CA, Norton L, Allison JP, McArthur HL. Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). Breast Cancer Symposium, San Francisco, CA. (#64), 9/2014.
  14. Page D, Yuan J, Diab A, Dong Z, Ginsberg A, Wong P, Emerson R, Redmond D, Blum B, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, Sung J, Brogi E, Morrow M, Solomon S, Sacchini V, Maybody M, Neville D, Robins H, Patil S, Wolchok J, Hudis C, Norton L, Allison J, Sharma P, McArthur H. Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts). Thirty-Fifth Annual Cancer Therapy & Research Center (CTRC) American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium, San Antonio, TX. 75(9 Supplement) (#P2-15-01), 5/2015.
  15. Skoulidis F, Byers L, Diao L, Papadimitrakopoulou V, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan JH, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong K-K, Zhang J, Sharma P, Mills GM, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba I, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, PA. 75(15 Supplement) (#968), 8/2015.
  16. Subudhi SK, Aparicio A, Gao J, Zurita A, John A, Logothetis C, Rao B, Vence L, Allison J, Emerson RO, Yusko E, Vignali M, Robins H, Sun JJ, Sharma P. Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer. 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015), National Harbor, MD. (#P106), November 4-8, 2015.
  17. Kim DW, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza I, Amaria R, Woodman S, Patel S, Davies M, yee C, Hwu W-J, Bernatchez C, Wargo J, Sharma P, Allison J, Hwu P, Tam A, Diab A. Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM). 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015), National Harbor, MD. (#P137), November 4-8, 2015.
  18. Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C-J, Vence LM, Logothetis C, Futreal A, Allison JP, Sharma P. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). Proceedings of the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, IL. (#e14506), 6/2016.
  19. Reilley M, Blando JM, Katkhuda R, Menter D, Sharma P, Allison JP, Kopetz S, Maru DM, Overman MJ. Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver mastectomy specimens: implications for immune targeting of proficient mismatch repair CRC. Proceedings of the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, IL. (#3520), 6/2016.
  20. Reilley M, Bailey AM, Subbiah V, Janku F, Naing A, Falchook GS, Karp DD, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Lim J, Bean SA, Bass A, Montes S, Vence LM, Sharma P, Allison JP, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. Proceedings of the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, IL. (#3054), 6/2016.
  21. Daver N, Basu S, Garcia-Manero G, Cortes J, Ravandi F, Kornblau S, Konopleva M, Andreeff M, Borthakur G, Jain N, Wierda W, Verstovsek S, Ruvolo P, Kadia T, Matthews J, Flores W, Yang H, Bueso-Ramos C, Somani N, Blando J, Allison J, Kantarjian H, Sharma P. Defining the immune checkpoint landscape of acute myeloid leukemia (AML). Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA. 76(14 Supplement) (#3205), 7/2016.
  22. Subudhi SK, Aparicio A, Gao J, Zurita-Saavedra A, Araujo JC, Logothetis CJ, Brinda KR, Allison JP, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Sharma P. Exploratory biomarkers that predict for clinical outcomes in a phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA. 76(14 Supplement) (#1402), 7/2016.
  23. Reuben A, Spencer CN, Prieto PA, Miller JP, Mao X, Chen W-S, Cheung H, Jiang H, Haymaker C, De Macedo MP, Garber HR, Chen P-L, Gopalakrishnan V, Austin-Breneman J, Hudgens CW, Roszik J, Hwu P, Woodman SE, Chin L, Davies MA, Amaria RN, Patel SP, Lazar AJ, Tetzlaff MT, Dwyer KC, Wistuba II, Sharma P, Allison JP, Zhang J, Futreal A, Cooper ZA, Wargo JA. Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA. 76(14 Supplement) (#2392), 7/2016.
  24. Cortez MA, Wang X, Ivan C, Schoenhals JE, Niknam S, Li A, Valdecanas D, Allison JP, Sharma P, Overwijk WW, Gomez D, Chang JY, Hahn S, Calin GA, Welsh JW. MicroRNA-mediated resistance to anti-PD1 therapy in lung cancer. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA. 76(14 Supplement) (#569), 7/2016.
  25. Morris V, Mahvash A, Vence L, Blando J, Wolff RA, Ohinata A, Ohaji C, Allison J, Sharma P, Eng C. NCI#9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, LA. 76(14 Supplement) (#CT131), 7/2016.
  26. Sharma N, Allison JP. Fc gamma receptor IV mediated depletion of tumor infiltrating regulatory T cells by anti-CTLA4 antibody is promoted by TLR1/2 agonist and hence its efficacy in anti-tumor combination therapy. Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY. 4(11 Supplement) (#B143), 11/2016.
  27. Massarelli E, Parra ER, Rogriguez-Canales J, Behrens C, Diao L, Blando J, Wang J, Byers LA, Wistuba II, Sharma P, Allison JP, Heymach JV. High OX-40 expression on the tumor immune infiltrate is a prognostic factor of better survival in non-small cell lung cancer. Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY. 4(11 Supplement) (#A084), 11/2016.
  28. Mok S, Duffy C, Du R, Allison JP. Increase antitumor activity of immunotherapy by blocking colony stimulating factor 1 receptor and tropomyosin receptor kinase. Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY. 4(11 Supplement) (#A146), 11/2016.
  29. Wei S, Allison J. Deep profiling of tumor infiltrating immune subsets by mass cytometry. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016), National Harbor, MD. (#P334), November 9-13, 2016.
  30. Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, Xiao L, Juliana L, Kornblau SM, Konopleva M, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, Allison J, Kantarjian HM, Sharma P. Defining the immune checkpoint landscape in patients (pts) with acute myeloid leukemia (AML). 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. 18(2900), Blood, 2016.
  31. Jain N, Basu S, Thakral B, Burger J, Thompson PA, Ferrajoli A, Estrov Z, Bueso-Ramos CE, Stingo F, Bassett RL Jr, Daver N, Kadia TM, Matthews J, Flores W, Somani N, Blando J, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Defining the immune checkpoint landscape in the bone marrow and peripheral blood of patients with chronic lymphocytic leukemia (CLL). 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. 128(2012), Blood, 2016.
  32. Sharma N, Allison J. Fc gamma receptor IV mediated depletion of tumor infiltrating regulatory T cells by anti-CTLA-4 antibody is promoted by TLR1/2 agonist and hence its efficacy in combination treatment of melanoma. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016), National Harbor, MD. (#P239), November 9-13, 2016.
  33. Allison J. Immune checkpoint blockade in cancer therapy: new insights, opportunities, and prospects for cures. American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, Boston, MA. 5(3 Supplement) (#IA08), 2016.
  34. Anderson C, Tang C, Schoenhals J, Tsouko E, Heymach J, de Groot P, Chang J, Hess KR, Diab A, Sharma P, Allison J, Naing A, Hong D, Welsh J. Neutrophil count predicts survival in patients on ipilimumab with radiation. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016), National Harbor, MD. (#P335), November 9-13, 2016.
  35. Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pemmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Lopez W, Thakral B, Bueso-Ramos CE, Blando J, O’Brien SM, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Nivolumab combined with ibrutinib for CLL and richter transformation: a phase II trial. 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. 128(59), 2016.
  36. Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pemmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Lopez W, Thakral B, Bueso-Ramos CE, Blando J, O’Brien SM, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG. Nivolumab combined with ibrutinib for CLL and richter transformation: a phase II trial. 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. 128(59), Blood, 2016.
  37. Daver N, Garcia-Manero G, Basu S, Cortes J, Ravandi F, Jabbour EJ, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Borthakur G, Pemmaraju N, Bueso-Ramos CE, Lopez JH, Blando J, Allison J, Kantarjian HM, Sharma P. Phase IB/II study of lirilumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML). 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. 128(1641), Blood, 2016.
  38. Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour EJ, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Pemmaraju N, Bueso-Ramos CE, Blando J, Hidalgo Lopez JE, Allison J, Kantarjianand HM, Sharma P. Phase IB/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML). 58th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. 128(763), Blood, 2016.
  39. Gopalakrishnan V, Spencer C, Reuben A, Karpinets T, Hutchinson D, Hoffman K, Prieto PA, Tetzlaff MT, Lazar A, Davies MA, Gershenwald JE, Jenq RR, Hwu P, Sharma P, Allison JP, Futreal A, Ajami N, Petrosino J, Daniel-MacDougall C, Wargo JA. Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL. (#2), 2/2017.
  40. Mok S, Duffy C, Du R, Allison JP. Blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase (Trk) improves antitumor efficacy of immunotherapy. American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, Boston, MA. 5(3 Supplement) (#PR01), 3/2017.
  41. Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, Tetzlaff MT, Lazar A, Hwu P, Hwu W-J, Glitza IC, Tawbi HA-H, Patel SP, Lee JE, Davies MA, Gershenwald JE, Futreal A, Sharma P, Allison JP, Jenq RR. Association of the diversity and composition of the gut microbiome with responses and survival in metastatic melanoma patients on anti-PD-1 therapy. Proceedings of the American Association of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL. (#3008), 6/2017.
  42. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudha SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis C, Wistuba II, Wargo JA, Blando JM, Sepulveda MA, Sun JJ, Sharma P. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL. (#5081), 6/2017.
  43. Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C-J, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Van Alstin M, Logothetis C, Futreal A, Allison JP, Sharma P. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL. (#5065), 6/2017.
  44. Chen W-S, Andrews MC, Spencer C, Tawbi HA-H, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu W-J, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL. (#9579), 6/2017.
  45. Daver NG, Garcia-Manero G, Cortes JE, Basu S, Ravandi F, Kadia TM, Borthakur G, Jabbour E, Dinardo CD, Pemmaraju N, Brandt M, Pierce S, Hussin N, Kornblau SM, Andreef M, Konopleva M, Ning J, Allison JP, Sharma P, Kantarjian HM. Phase IB/II study of Iirilumab with azacytidine (AZA) in relapsed AML. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL. (#e18505), 6/2017.
  46. Daver NG, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreef M, Ning J, Kornblau S, Kadia TM, Dinardo CD, Konopleva M, Allison JP, Kantarjian HM, Sharma P. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL. (#7026), 6/2017.
  47. Reilley M, Basu S, Katkhuda R, Patterson N, Chen T, Blando JM, Menter D, Maru DM, Allison JP, Kopetz S, Sharma P, Overman MJ. Prognostic implications of TAMs in colorectal cancer hepatic metastases. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL. (#3574), 6/2017.
  48. Gao J, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campell M, Ng CS, Slack RS, Rao P, Allison JP, Blando JM, Vence LM, Basu S, Zhao H, Chen T, Chen H, Sharma P. Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC. 77(13 Supplement) (#CT083), 7/2017.
  49. Mok S, Duffy CR, Allison JP. Effects of anti-ctla-4 and anti-pd-1 on memory T-cell differentiation and resistance to tumor relapse. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC. 77(13 Supplement) (#1685), 7/2017.
  50. Gopalakrishnan V, Spencer C, Reuben A, Prieto P, Vicente D, Karpinets TV, Hudgens CW, Hutchinson DS, Tetzlaff M, Lazar A, Davies MA, Gershenwald JE, Jenq R, Hwu P, Sharma P, Allison J, Futreal A, Ajami N, Petrosino J, Daniel-MacDougall C, Wargo JA. Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC. 77(13 Supplement) (#2672), 7/2017.
  51. Williams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Al-Hamal Z, Konopleva M, Ning J, Xiao L-C, Hidalgo Lopez J, Kornblau S, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, Alatrash G, Allison JP, Kantarjian HM, Sharma P, Daver N. Checkpoint expression by acute myeloid leukemia (AML) and the immune microenvironment suppresses adaptive immunity. 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA. 130(185), Blood, 2017.
  52. Wei SC, Levin JH, Pe’er D, Allison JP. Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1 checkpoint blockade. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC. 77(13 Supplement) (#592), April 1-5, 2017.
  53. Wei S, Levine J, Cogdill A, Zhao Y, Anang N-A, Andrews M, Sharma P, Wang J, Wargo J, Pe’er D, Allison J. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD. (#P379), 2017.
  54. Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Andrews M, Karpinets T, Vicente D, Prieto P, Hoffman K, Wei S, Cogdill A, Sanchez ER, McAllister F, Wong M, Davies M, Lazar A, Gershenwald J, Ajami N, Cooper Z, Petrosino J, Daniel-MacDougall C, Tetzlaff M, Allison J, Sharma P, Jenq R, Wargo J. Diversity and composition of the gut microbiome influences responses to anti-PD1-therapy through beneficial changes in innate and adaptive immunity. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD. (#O30), November 8-12, 2017.
  55. Sharma P, Sohn JH, Shin SJ, Oh D-Y, Keam B, Lee HJ, Canon J-L, Kalinka-Warzocha E, Langenberg M, Allison J, Ben Y, Kataria R, Ferro S, Asubonteng K, Dirix L. Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD. (#P213), 2017.
  56. Allison, JP. Immune checkpoint blockade in cancer therapy: cellular mechanisms of anti-CTLA-4 and anti-PD1. Proceedings of the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, June 2, 2017.
  57. Reuben A, Gittelman R, Zhang J, Chen R, Quek K, Vence L, Fernandez-Cubelo I, Behrens C, Gao J, Yusko E, Emerson R, Benzeno S, Vignali M, Tipton C, Jalali A, Lee W-C, Li J, Wu X, Ye Y, Eterovic A, Little L, Gumbs C, Goplakarishnan V, Bernatchez C, Haymaker C, Forget M-A, Federico L, Cascone T, Robins H, Roarty E, Rodriguez J, Parra E, Wargo J, Allison J, Sharma P, Zhang J, Lee J, Sepesi B, Swisher S, Gibbons D, Heymach J, Futreal A, Wistuba I, Zhang J. Immune, molecular and T cell repertoire landscape of 235 resected non-small cell lung cancers, paired normal lung and peripheral blood mononuclear cells. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD. (#O67), 2017.
  58. Jaiswal A, Pudakalakatti S, Dutta P, Arthur L, Bartkowiak T, Ager C, Ivan C, Davies MA, Allison JP, Davis RE, Wargo J, Bhattacharya PK, Hong D, Curran MA. Metabolic adaptations establish immunotherapy resistance in melanoma. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD. (#O26), November 8-12, 2017.
  59. Reddy SM, Amaria RN, Spencer CN, Tetzlaff M, Reuben A, Andrews M, Wang L, Woodman S, Zhu H, Blando J, Vence L, Zhang S, Jiang H, Gopalakrishnan V, Hudgens C, Wani K, Tawbi H, Diab A, Glitza I, Patel S, Hwu W-J, Wong M, Hwu P, Cormier J, Lucci A, Royal R, Lee JE, Simpson L, Burton EM, Gershenwald JE, Ross M, Allison J, Sharma P, Davies M, Wargo J. Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings. 32nd Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2017), National Harbor, MD. (#O15), November 8-12, 2017.
  60. Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, Flores W, Matthews J, DiNardo CD, Borthakur G, Konopleva M, Allison J, Sharma P, Kantarjian HM. Nivolumab (Nivo) with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) and frontline elderly AML. 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA., 2017.
  61. Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour DJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, Flores W, Matthews J, DiNardo CD, Borthakur G, Konopleva M, Allison J, Sharma P, Kantarjian HM. Nivolumab (Nivo) with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) and frontline elderly AML. 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA. 130(1345), Blood, 2017.
  62. Ravandi F, Daver N, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia T, Boddu BC, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Allison J, Sharma P, Pierce S, Brandt M, Pike A, Cortes JE, Kantarjian HM. Phase 2 study of combination of cytarabine, idarubicin, and nivolumab for initial therapy of patients with newly diagnosed acute myeloid leukemia. 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA. 130(815), Blood, 2017.
  63. Gao J, Karam JA, Tannir NM, Slack R, Ahrar K, Rao P, Ng CS, Jonasch E, Campbell MT, Matin SF, Zurita AJ, Wang J, Blando JM, Zhao H, Vence LM, Basu S, Chen H, Allison JP, Wood CG, Sharma P. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx). American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, Chicago, IL. (#4520), June 2, 2018.
  64. Shi LZ, Gao J, Vence L, Brando J, Allison J, Sharma P. Adoptive transfer of tumor antigen-specifıc CTLs requires antiCTLA-4 and anti-PD-1 to drive tumor eradication. American Association for Cancer Research (AACR) Annual Meeting, Chicago, IL. (#2984), April 14-18, 2018.
  65. Mok S, Duffy CR, Allison JP. Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse. American Association for Cancer Research (AACR) Annual Meeting, Chicago, IL. (#2984), April 14-18, 2018.
  66. Sharma P, Dirix L, De Vos FYFL, Allison JP, Decoster L, Zaucha R, Park JH, Vanderwalde AM, Kataria RS, Ferro S, Patel G, Ben YB, Oh D-Y. Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma. 2018 Gastrointestinal Cancers Symposium, San Francisco, CA. (#202691), 2018.
  67. Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VL II, Sharma P, Allison JP, Blando JM, Maru DM, Overman MJ, Kopetz S. Phosphatidylinositol 3-kinase (PI3K) pathway activation is associated with increased immune checkpoint expression in colorectal cancer (CRC) patients. 2018 Gastrointestinal Cancers Symposium, San Francisco, CA. (#204291), 2018.
  68. Gao H-X, Bhattacharya S, Matheny CJ, Yanamandra N, Zhang S-Y, Emerich H, Li Y, Bojczuk P, Shi H, Wang W, Hopson C, Fu T, Allison JP, Sharma P, Smothers JF, Srinivasan R, Hoos A. Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy. American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, Chicago, IL. (#12055), June 4, 2018.
  69. Keung EZ, Glitza IC, Burton E, Amaria RN, Patel SP, Diab A, Yee C, Wong MK, Hwu W-J, Hwu P, Woodman SE, Tetzlaff MT, Trujillo-Conley N, Milton DR, Davies MA, Rai K, Fernandez I, Blando JM, Vence LM, Sharma P, Allison JP, Wargo JA, Tawbi H. The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on immune infiltrates in metastatic melanoma (MM). American Association for Cancer Research Annual Meeting, Chicago, IL. (#5711), April 14-18, 2018.
  70. Reuben A, Gittelman R, Zhang K, Quek K, Vence LM, Behrens C, Chen R, Fujimoto K, Chow C-W, Wu X, Allison JP, Sharma P, Zhang J, Lee JJ, Sepesi B, Gibbons DL, Heymach J, Futreal A, Wistuba II, Zhang J, ICON-PROSPECT Team. The T cell receptor landscape is associated with survival in non-small cell lung cancer. 2018 American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium, San Francisco, CA. (#204857), 2018.
  71. Williams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Lopez JH, Kornblau S, Andreeff M, Bueso-Ramos CE, Blando JM, Alatrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML. American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, Chicago, IL. (#7016), June 4, 2018.
  72. De Groot JF, Penas-Prado M, Mandel JJ, O’Brien BJ, Weathers SS, Zhou S, Hunter K, Alfaro-Munoz K, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, Ferguson SD, Yuan Y, Vence LM, Allison JP, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, Chicago, IL. (#2008), June 1, 2018.

Book Chapters

  1. Ferrone S, Pellegrino MA, Belvedere M, Reisfeld RA, Curry R, Allison JP. Human B cell antigens: biological and immunogenic properties. In: Protides of Biological Fluids, 25th Colloquium 1977. 25. Ed(s) Peeters H. Oxford: Pergamon Press, 645-52, 1978.
  2. Walker LE, Allison JP, Silver J, Pellegrino MA, Reisfeld RA, Ferrone S. Is serological polymorphism of human DR antigens determined by structural differences in the smaller (beta) chain? In: Cell Biology and Immunology of Leukocyte Function. Ed(s) Quastel MR. New York: Academic Press, 271-6, 1979.
  3. Walborg EF Jr, Starling JJ, Davis EM, Hixson DC, Allison JP. Plasma membrane alterations during carcinogenesis. In: Carcinogens: Identification and Mechanisms of Action. Ed(s) Griffin AC, Shaw CR. New York: Raven Press, 381-98, 1979.
  4. Ferrone S, Pellegrino M, Allison JP. Rabbit complement in the cytotoxic test with antibody-coated nucleated cells: properties and role of human antigens reactive with rabbit natural antibodies. In: HLA Antigens in Clinical Medical and Biology. Ed(s) Ferrone S, Gorini L, Curtoni ES. New York: Garland Press, 28-36, 1979.
  5. Belvedere M, Allison JP, Reisfeld R, Pellegrino M, Ferrone S. Serum HLA antigens: serological and immunogenic properties. In: HLA Antigens in Clinical Medical and Biology. Ed(s) Ferrone S, Forini L, Curtoni ES. New York: Garland Press, 19-27, 1979.
  6. Callahan GN, Ferrone S, Allison JP, Reisfeld RA. Histocompatibility and tumor-associated antigens in serum. In: Handbook of Cancer Immunology. 8. Ed(s) Waters H. New York: Garland STPM Publishing Company, 79-104, 1981.
  7. Allison JP, Hixson DC, Lund JN, Chesner JE, Ridge LL, Leger MJ, McEntire KD, Walborg EF Jr. Monoclonal antibodies as probes of surface antigenic alteration during experimental hepatocarcinogenesis in the rats. In: Membranes in Tumour Growth. Ed(s) Galeotti T, Cittidini A, Neri G, Papa S. Amsterdam: Elsevier Biomedical Press, 599-606, 1982.
  8. Hixson DC, Allison JP, Chesner JE, Leger MJ, Ridge LL, Thomas MW, Walborg EF Jr. Variation in the expression and structure of a subset of normal bile canalicular glycoproteins on transplantable hepatocellular carcinomas. In: Membranes in Tumour Growth. Ed(s) Galeotti T, Cittidini A, Neri G, Papa S. Amsterdam: Elsevier Biomedical Press, 19-27, 1982.
  9. Hixson DC, Ponce MDL, McEntire D, Chesner J, Lund JA, Allison JP, Walborg EF Jr. Identification of a liver glycoprotein which is present on both hepatocytes and extracellular biomatrix. 34th Falk Symposium. In: Structural Carbohydrates in the Liver, 577-85, 1983.
  10. Allison JP, McIntyre BW, Irvin J, Bloch D, Kitto GB. Monoclonal antibody to tumor specific epitope to murine lymphoma cells: Use in characterization of antigen and in immunotherapy. In: Hybridomas and Cellular Immortality. Ed(s) Tom BH, Allison JP. New York: Plenum Publishing Company, 201-20, 1983.
  11. Marrack P, Kubo R, Haskins K, Hannum C, White J, Pigeon M, Endres R, Shimonkevitz R, McIntyre B, Allison JP, Trowbridge I, Kappler J. T Cell hybridomas’ use in studying T cell receptors for antigen plus MHC. In: Progress in Immunology V. Ed(s) Yamamura Y, Tada T. New York: Academic Press, 735-54, 1983.
  12. Allison JP, McIntyre BW. The murine T cell antigen receptor. In: Progress in Immunology V. Ed(s) Yamamura Y, Tada T. New York: Academic Press, 755-62, 1983.
  13. Allison JP, McIntyre BW, Cheung FCY, Lanier LL. Molecular characterization of the murine T cell antigen receptor. In: Regulation of the Immune System, UCLA Symposia on Molecular and Cellular Biology. 18. Ed(s) Sercarz E, Cantor H, Chess L. New York: Alan R. Liss, Inc., 1984.
  14. McIntyre BW, Lanier LL, Allison JP. The murine T cell receptor. In: Mitogen Specific Receptors and Factors. I. Boca Raton: CRC Press, Inc., 66-75, 1986.
  15. Allison JP, Parham P. Evolution of the T cell antigen receptor. In: Evolution and Vertebrate Immunity. Ed(s) Kelsoe G, Schulze DH. Austin: University of Texas Press, 213-24, 1987.
  16. Allison JP, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S, Brunner M, Krummel M. . A role for CTLA-4 mediated inhibitory signals in peripheral T cell tolerance? In: Novartis Foundation Symposium 215, Immunological Tolerance. Ed(s) Bock GR, Good JA. Hoboken: John & Sons, 1988.
  17. Allison JP, Havran WL, Poenie M, Kimura J, DeGraffenreid L, Ajami S, Duwe G, Weiss A, Tsien R. Expression and function of CD3 on murine thymocytes. In: UCLA Symposia on Molecular and Cellular Biology, New Series. 73. Ed(s) Kappler J, Davis MM. New York: Alan R. Liss, Inc., 33-45, 1988.
  18. Havran WL, Allison JP. Fetal thymic origin of epithelial gamma delta T cells. In: Cellular Immunity and the Immunotherapy of Cancer, UCLA Symposia on Molecular and Cellular Biology, New Series. 135. Ed(s) Lotze MT, Finn OJ. New York: Wiley-Liss, 23-30, 1990.
  19. Allison JP, Asarnow DM, Bonyhadi M, Carbone A, Havran WL, Nandi D, Noble J. Gamma delta-T cells in murine epithelia: origin, repertoire, and function. In: Adv Exp Med Biol. 292, 3rd. Ed(s) Gupta S, Paul WE, Cooper MD, Rothenberg EV. New York: Plenum Press, 63, 1991. PMID: 1835264.
  20. Allison JP, Havran WL. The immunobiology of T cells with invariant delt gamma antigen receptors. In: Annual Review of Immunology. 9. Ed(s) Paul WE. Palo Alto: Annual Reviews Inc., 679-705, 1991.
  21. Krummel M, Allison JP. B7-mediated co-stimulation of T cells: CTLA-4 can deliver inhibitory signals. In: Genetic Models of Immune and Inflammatory Diseases. Ed(s) Abbas AK, Flavell RA. New York: Springer-Verlag, 138-46, 1996.
  22. Hurwitz AA, Leach DR, van Elsas A, Townsend SE, Allison JP. Manipulation of T cell activation in the anti-tumor immune response. In: The Biology of Tumors. Ed(s) Mihich E, Croce C. New York: Plenum Press, 213-9, 1998.
  23. Chambers CA, Allison JP. CTLA-4 – The costimulatory molecule that doesn’t: regulation of T-cell responses by inhibition. In: Cold Spring Harbor Symposia on Quantitative Biology. 64. Cold Spring Harbor Laboratory, 303-12, 1999.
  24. Hurwitz AA, van Elsas A, Leach DR, Ziskin J, Villasenor J, Truong T, Allison JP. Manipulation of T cell activation to generate antitumor CTLs. In: Cytotoxic Cells: Basic Mechanisms and Medical Applications. Ed(s) Sitkovsky MV, Henkart PA. Philadelphia: Lippincott Williams & Wilkins, 385-93, 1999.
  25. Allison JP, Hurwitz AA, van Elsas A, Kwon E, Sullivan T, Foster B, Greenberg N. CTLA-4 blockade in tumor immunotherapy. In: Principles and Practice of the Biologic Therapy of Cancer. 25, 3rd. Ed(s) Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins, 890-5, 2000.
  26. Allison JP. Modulation of the inhibitory effects of CTLA-4 in the enhancement of immunologic responses against cancer. In: Progress in Oncology. 2. Ed(s) DeVita VT, Hellman S, Rosenberg SA. Sudbury, Massachusetts: Jones & Bartlett, 23-35, 2002.
  27. Peggs KS, Quezada SA, Allison JP. Checkpoint blockade and combinatorial immunotherapies. In: General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology. Ed(s) Kaufman HL, Wolchok JD. Springer, The Netherlands, 363-90, 2007.
  28. Subudhi SK, Scher HI, Allison JP. CTLA-4 inhibitors in castration-resistant prostate cancer. In: Targeted Therapies for Castration-Resistant Prostate Cancer. Ed(s) Scardino PT. Future Medicine: London, UK, 92-102, 2011.

Books (edited and written)

N/A

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Associate Editor, Journal of Immunology, American Association of Immunologists (AAI), 1987-1993

Transmitting Editor, International Immunology, Oxford University Press, 1988-present

Editorial Board, Developmental Immunology, 1989-present

Associate Editor, Immunity, 1997-present

Scientific Editor, Cancer Discovery, American Association for Cancer Research (AACR), 2011-present

Editor-in-Chief, Cancer Immunity, Cancer Research Institute (CRI), 2012-present

Member of Editorial Review Board

Reviewing Editor, Science, American Association for the Advancement of Science (AAAS), 1985-1987

Section Editor, Journal of Immunology, American Association of Immunologists (AAI), 1993-1996

Editorial Board, Journal of Experimental Medicine, 1993-1997

Editorial Board, Proceedings of the National Academy of Science (PNAS) U S A, 2002-2005

Editorial Board, Journal of Clinical Investigation, The American Society for Clinical Investigation (ASCI), 2003-present

Journal Reviewer

N/A

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution – GSBS

Formal Teaching

Courses Taught

Instructor, Application of Tumor Immunology in the Clinical Setting, GSBS, Course Number: GS06 1123, Course Hours: 2

Fall, 2013

Instructor, Foundations of Biomedical Research, GSBS, Course Number: GS21 1017, Course Hours: 2

Fall, 2014-2015

Instructor, Cancer Biology, GSBS, Course Number: GS04 1063, Course Hours: 2

Spring, 2015-2016

Instructor, The Biology of Cancer Metastasis, GSBS, Course Number: GS04 1093, Course Hours: 1

Fall, 2015-2016

Instructor, Basic and Translational Cancer Biology, GSBS, Course Number: GS04 1233, Course Hours: 2

Spring, 2016-2017

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

Committee Member, GSBS, David Mitchell, MS, 11/1978-12/1980

Committee Member, GSBS, Alexandra Howell, PhD, 10/1980-12/1982

Committee Member, GSBS, Cheng Peng, PhD, 10/1980-3/1984

Committee Member, GSBS, Thomas Saunders, PhD, 4/1982-6/1984

Committee Member, GSBS, Sandra Stettner, PhD, 12/1983-3/1985

Research Co-Mentor, GSBS, Ashvin Jaiswal, PhD, 9/2013-present

Committee Member, GSBS, Casey Ager, PhD, 10/2014-present

Research Mentor, GSBS, Whijae Roh, PhD, 12/2014-12/2017

Committee Chair, GSBS, Colm Duffy, PhD, 5/2015-present

Committee Member, GSBS, Taylor Chrisikos, PhD, 11/2016-present

Committee Member, GSBS, Swetha Anandhan, PhD, 11/2017-present

Committee Member, GSBS, Jeffrey Ackroyd, PhD, 12/2017-present

Supervisory Committees

N/A

Examining Committees

Committee Member, GSBS, Thomas Saunders, 6/1981

Committee Member, GSBS, Rumi Lee, 10/2017

Direct Supervision

Undergraduate and Allied Health Students

Research Mentor, Benjamin Whitfield, 6/2016-8/2016

Research Mentor, Reginald Du, 6/2016-8/2016

Medical Students

N/A

Graduate Students

Research Mentor, Advisory Committee, Colm Duffy, 8/2014-present

Research Mentor, Advisory Committee, Alexandria Cogdill, 5/2017-present

Research Mentor, Advisory Committee, Xiaojie Yang, 1/2018-present

Research Mentor, Advisory Committee, Renee Chin, 5/2019-present

Postdoctoral Research Fellows

Research Mentor, Tsvetelina Hoang, PhD, 2001-2009

Research Mentor, Rajarshi Bhadra, PhD, 2012-2014

Research Mentor, Naveen Sharma, PhD, 2012-2015

Research Mentor, Xiaozhou Fan, PhD, 2012-2017

Research Mentor, Spencer Christopher Wei, PhD, 5/2014-10/2018

Research Mentor, Didem Agac, PhD, 6/2018-present

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

Research Mentor, JianJun Gao, PhD, 2016-present

Teaching Outside Current Institution

Formal Teaching

Courses Taught

Faculty, Evolution and Regulation of the Immune System, American Association of Immunologists (AAI)

1984-1985

Convener and Faculty, The Molecular and Cellular Biology of the T Lymphocyte, All India Institutes of Medical Sciences, New Delhi

1987

Faculty, Advanced Course in Immunology, Federation of European Biological Societies (FEBS), Greece

1992

1996

2000

Faculty, Advanced Course in Immunology, American Association of Immunologists (AAI), Berkeley, CA

1995-2000

Faculty, Experimental Genetics of the Laboratory Mouse in Cancer Research, Jackson Laboratories, Bar Harbor, ME

2003-2005

Speaker, Federation of Clinical Immunology Societies (FOCIS): Advanced Course in Basic & Clinical Immunology, FOCIS, Phoenix, AZ

2006

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Marcella Fasso, PhD, 1999-2004

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Peter Savage, PhD, 2000-2009

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Michael Curran, PhD, 2001-2012

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Rebecca Waitz, PhD, 2002-2010

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Emily Corse, PhD, 2003-2012

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Karl Peggs, MD/PhD, 2004-2007

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Xing Xing Zhang, MD, 2004-2008

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Manuel Sepulveda, PhD, 2004-2009

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Sergio Quezada, PhD, 2004-2010

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Cenk Sumen, PhD, 2006-2009

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Joyce Wei, PhD, 2009-2012

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Sumit Subudhi, PhD, 2009-2013

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Virgina Pedicord, PhD, 2010-2012

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Katharina Kreymborg, PhD, 2010-2013

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Dmitriy Zamarin, PhD, 2011-2013

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Rikke Holmgaard, PhD, 2011-2013

Research Mentor, Memorial Sloan-Kettering Cancer Center (MSKCC), Tyler Simpson, PhD, 2012-2013

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

Keystone Symposium on T Cell Activation, Keystone Symposium on Molecular and Cellular Biology, Denver, CO, Co-Chair, 1994

Keystone Symposium on T Cell Development, Keystone Symposia on Molecular and Cellular Biology, Banff, Canada, Co-Chair, 2004

3rd Basel Immunology Focus Symposium, University of Basel, Basel, Switzerland, Speaker, 8/2013

2014 Ross Prize in Molecular Medicine: Advances in Immunomodulation Symposium, The New York Academy of Sciences, New York, NY, Invited Speaker, 6/2014

Innovation in Cancer Science and Therapy Symposium, Sanofi/MIT, Cambridge, MA, Speaker, 6/2014

2014 Tang Prize Award Ceremony & Lecture Series, Tang Prize Foundation, Taipei, Taiwan, Award Winner & Speaker, 9/2014

26th Annual Usah Mahajani Symposium, The Usha Mahajani Foundation, La Jolla, CA, Keynote Speaker, 9/2014

2014 Cancer Research Institute (CRI) Symposium Cancer Immunotherapy: Out of the Gate, CRI, New York, NY, Speaker, 10/2014

2014 Gairdner Foundation Symposium, The Gairdner Foundation, Vancouver, Canada, Speaker, 10/2014

2014 IOM Annual Meeting – The World Within: The Human Microbiome in Health & Disease, Institute of Medicine, Washington, DC, Speaker, 10/2014

Breakthrough Prize in Life Sciences Symposium, University of California, San Francisco & University of California, Berkley, San Francisco, CA, Speaker, 11/2014

The Alexander Bodini Foundation Prize for Scientific Excellence in Medicine Scientific Research Symposium, American Italian Cancer Foundation, New York, NY, Speaker, 11/2014

Alando J. Ballantyne Lectureship, The University of Texas MD Anderson Cancer Center, Houston, TX, Keynote Speaker, 2015

Japanese Society of Medical Oncology (JSMO) International Symposium on ImmunoOncology, JSMO, Tokyo, Japan, Keynote Speaker, 2016

The Robert Lefkowitz Distinguished Lecture, Duke University School of Medicine, Durham, NC, Keynote Speaker, 2016

Second Annual Immuno-Oncology Young Investigator’ Forum, Young Investigator Programs, Houston, TX, Moderator, 3/2016

Stem for Life Foundation and the Vatican’s Pontifical Council for Culture, The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact, Rome, Italy, Speaker, 4/2016

Prostate Cancer Foundation, 2016 Coffey-Holden Prostate Cancer Academy, San Diego, CA, Keynote Speaker, 6/2016

Tumor Immunology and Immunotherapy, America Association for Cancer Research (AACR), Boston, MA, Co-Chair, 10/2016

The University of Texas MD Anderson Cancer Center, Regional Immunology Conference, Houston, TX, Keynote Speaker, 11/2016

7th Annual Henry Mihich Lecture, Roswell Park Cancer Institute, Buffalo, NY, Keynote Speaker, 2017

Presentations at National or International Conferences

Invited

Mobilizing the Immune System to Treat Cancer: Immune Checkpoint Strategies, American Society of Clinical Oncology (ASCO), ASCO, Chicago, IL, 6/2/2012

Immune Checkpoint Blockade in Cancer Therapy: New Opportunities, 10th International Workshop Immunotherapy 2012, Center of Molecular Immunology (CIM), National Institute of Oncology & Radiobiology (INOR), Latin American Association of Immunology (ALAI), Havana, Cuba, 11/12/2012

Immunomechanisms/Immune Perturbation, American Association for Cancer Research (AACR) Translational Cancer Research for Basic Scientists, AACR, Boston, MA, 11/30/2012

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, American Association for Cancer Research (AACR) Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances, AACR, Miami, FL, 12/4/2012

Tumor Microenvironment, Keystone Symposia on Cancer Immunology and Immunotherapy, Vancouver, British Columbia, Canada, 1/27/2013

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, 9th American Association for Cancer Research (AACR)-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research, AACR/Japanese Cancer Association, Maui, HI, 2/21/2013

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, Foundation IPSEN, Taormina, Sicily, Italy, 3/12/2013

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, American Association for Cancer Research (AACR), AACR Annual Meeting 2013, Washington, DC, 4/6/2013

Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy, Stand Up To Cancer (SU2C), American Association for Cancer Research (AACR) Annual Meeting 2013, Washington, DC, 4/7/2013

Checkpoint Blockade and Mutation Induces Neoantigens, American Association for Cancer Research (AACR), AACR Annual Meeting 2013, Washington, DC, 4/8/2013

Mobilizing the Immune System for Cancer Therapy, American Association for Cancer Research (AACR)-Cancer Research Institute (CRI), AACR-CRI, Washington, DC, 4/10/2013

Immunotherapy: Checkpoint Blockade and Cancer, Frontiers in Prostate Cancer Translational Research, Prostate Cancer Foundation, Athens, Greece, 5/17/2013

Tumor Immunity and Checkpoint Blockade, Gordon Research Conference (GRC) – Angiogenesis Program, GRC, New Port, RI, 8/6/2013

Immune Checkpoint Blockade in Cancer Therapy: New Insights & Opportunities, 15th International Congress of Immunology, Novartis, Milan, Italy, 8/21/2013

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, Friends of Cancer Research Conference on Clinical Cancer Research (CCR), Friends of Cancer Research, Washington, DC, 11/7/2013

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, 2014 American Association for Cancer Research (AACR) Annual Meeting, AACR, San Diego, CA, 4/2014

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, 2014 Gordon Research Conference (GRC), GRC, Newport, RI, 6/5/2014

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, Molecular Therapeutics of Cancer Research Conference, Cancer Molecular Therapeutics Research Association, Pacific Grove, CA, 7/15/2014

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, 45th International Symposium of the Princess Takamatsu Cancer Research Fund, Princess Takamatsu Cancer Research Fund, Tokyo, Japan, 11/2014

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, 2014 Society for Immunotherapy of Cancer, Society for Immunotherapy of Cancer, National Harbor, MD, 11/6/2014

Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities, and Prospects for a Cure, American Society of Clinical Oncology (ASCO), ASCO, Chicago, IL, 5/31/2015

Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities, and Prospects for a Cure, American Society of Clinical Oncology (ASCO), ASCO, Chicago, IL, 6/1/2015

Immune Checkpoint Blockade in Cancer Therapy, Prostate Cancer Foundation, The Coffey-Holden Prostate Cancer Academy, San Diego, CA, 6/23/2016

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, International Symposium on Immuno-Oncology, 2016 Japanese Society of Medical Oncology (JSMO), Tokyo, Japan, 7/30/2016

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, 16th International Congress of Immunology, Australasian Society for Immunology Inc., Melbourne, Australia, 8/21/2016

Immune Checkpoint Blockade in Cancer Therapy: Cellular Mechanisms of Anti-CTLA-4 and Anti-PD1, American Society of Clinical Oncology (ASCO), ASCO, Chicago, IL, 6/2/2017

Other, Including Scientific Exhibitions

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, Cancer Research Institute (CRI) 2013 Symposium, CRI, New York, NY, 9/30/2013

Cancer Research Institute (CRI)-McKinsey Strategic Planning Workshop, CRI, New York, NY, 10/8/2016

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, American Association for the Advancement of Science (AAAS), Austin, TX, 2/18/2018

Seminar Invitations from Other Institutions

Beyond Immune Checkpoint Blockade: Manipulation of T Cell Regulatory Circuits in Cancer Therapy, Sanford Immunology Program Seminar Series, Stanford, Immunology, Stanford, CA, 1/8/2013

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, Harvard University, Department of Stem Cell and Regenerative Biology, Cambridge, MA, 3/5/2013

Tumor Immunity and Checkpoint Blockade, Salk Institute 3rd Symposium: Mechanisms & Models of Cancer, Salk Institute for Biological Studies, La Jolla, CA, 8/8/2013

Immune Checkpoint Blockade in Cancer Therapy: Insights, Opportunities, and Prospects for Cures, Sister Institution Signing Ceremony-Istituto Superiora della Sanita (ISS), Global Academic Programs, The University of Texas MD Anderson Cancer Center, Rome, Italy, 5/2/2016

Lectureships and Visiting Professorships

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, Bruckner Foundation Lecture Series, Washington University, Pathology and Immunology, St. Louis, MO, 4/18/2014

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, Mike Hogg Distinguished Lecturer Series, The University of Texas at Austin/Smithville, Immunology, Austin, TX, 5/2014

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, Croucher Summer Course: Advances in Immunology in Health and Disease, Croucher Summer Course 2014, Department of Medicine, Hong Kong, China, 7/2014

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, 2015 Alando J. Ballantyne Lectureship, The University of Texas MD Anderson Cancer Center, Head and Neck Surgery, Houston, TX, 10/2/2015

Immune Checkpoint Blockade in Cancer Therapy: Insights, Opportunities, and Prospects for Cures, The Robert Lefkowitz Distinguished, Duke University School of Medicine, Durham, NY, 1/5/2016

Immunology and Immunotherapy, Fourth American Association for Cancer Research (AACR) International Conference on Frontiers in Basic Cancer Research, American Association for Cancer Research (AACR), Philadelphia, PA, 10/23/2016

Other Presentations at State and Local Conferences

Immune Checkpoints & Cancer, Texas Cancer Vaccine Symposium, Baylor Research Institute, Immunology Research, Dallas, TX, 1/22/2013

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, Cancer Biology and Therapeutics, Cold Spring Harbor Laboratory, New York, NY, 4/24/2013

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, T Cell Function and Modulation Conference, AgonOx, Maui, HI, 4/29/2013

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, 2013 Texas Fresh Air Academia Industry Roundtable, The University of Texas System, Office of Health Affairs, Austin, TX, 9/25/2013

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, 2014 Massry Prize Lecture, Meira and Shaul G. Massry Foundation, Los Angeles, CA, 10/2014

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, 2014 American Physician Scientists Association South Regional meeting, The University of Texas Health MD/PhD Program, Houston, TX, 11/1/2014

Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, 2014 Loisa Gross Horwitz Prize Lecture, Columbia University, Genetics and Development, New York, NY, 11/12/2014

Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities and Prospects for a Cure, Recent Advances in the Development of Combinatorial Therapies for Cancer, John S. Dunn Gulf Coast Consortium for Chemical Genomics, Texas A&M Health Science Center, Institute of Biosciences and Technology, Houston, TX, 6/10/2015

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, AACR, Boston, MA, 10/20/2016

Immune Checkpoint Blockade in Cancer Therapy: Insights, Opportunities, and Prospects for Cures, 2016 Cancer Biology Program Fall Retreat, Cancer Biology, The University of Texas MD Anderson Cancer Center (2016 Cancer Biology Program Fall Retreat), Cancer Biology, Galveston, TX, 10/29/2016

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, Texas Regional Immunology Conference, The University of Texas MD Anderson Cancer Center, Immunology, Houston, TX, 11/10/2016

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, 3rd Annual CN Partner Meeting: Immunotherapy, Cancer Network Partner, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/10/2016

Immunotherapy, The University of Texas MD Anderson Cancer Center Network 3rd Annual Partner Meeting, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/10/2016

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, Fudan-Zhongzhi Science Award Ceremony, Fudan University, Shanghai, China, 12/16/2016

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, 2017 Warren Triennial Symposium, Harvard Medical School, Boston, MA, 4/4/2017

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, Han-Mo Koo Memorial Lecture, Van Andel Institute, Grand Rapids, MI, 5/4/2017

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, ARS 2017 Annual Meeting Janeway Lecture, The Broadmoor, Colorado Springs, CO, 5/6/2017

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, Wolf Foundation Prize Ceremony, Land of Israel Museum, Tel Aviv, Israel, 6/8/2017

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy, Boston Marriott Copley Hotel, Boston, MA, 9/30/2017

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and Prospects for Cures, Warren Alpert Prize Symposium, Harvard Medical School, Boston, MA, 10/5/2017

Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, National Cancer Institute (NCI) Center of Excellence in Immunology Tri-Annual Meeting, National Institutes of Health, Bethesda, MD, 10/12/2017

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

International Union Against Cancer

Member, American Cancer Society (ACS) Fellowship Committee, 1985-1989

Chair, American Cancer Society (ACS) Fellowship Committee, 1989-1994

Other

Board Member, Midwinter Conference of Immunologists, 1986-1988

Consultant, NeXstar Pharmaceuticals, Inc., 1996-2000

Member, Scientific Advisory Board, IDEC Pharmaceuticals Corporation, 1996-2002

Member, Scientific Advisory Board, Tularik, Inc., 1996-2004

Consultant, Cell Genesys, Inc., 1997-2009

Consultant, Medarex, 1997-2009

Member, Scientific Advisory Board, Cerus Corporation, 2001-2007

Member, Scientific Advisory Board, VaxInnate, 2002-2007

Member, External Advisory Committee, North-Central California Center for AIDS Research, 2002

Member, Scientific Advisory Board, Heat Biologics, 2010-2012

Member, Advisory Board, Jounce Therapeutics, 2012-present

Scientific Advisory Board, Ontario Institute for Cancer Research, 2013-present

Member, Scientific Advisory Board, Kite Pharmaceutical, Inc., 2015-2018

Member, Scientific Advisory Board, Neon Therapeutics, 2015-present

Member, Scientific Advisory Board, Amgen, 2016-present

Member, Scientific Advisory Board, BioAtla, LLC, 2017-present

Member, Scientific Advisory Board, Codiak Biosciences, Inc., 2018-present

Member, Scientific Advisory Board, Forty-Seven, Inc., 2018-present

Member, Scientific Advisory Board, ImaginAb, 2018-present

Member, Scientific Advisory Board, TapImmune, Inc., 2018-present

Member, Scientific Advisory Board, Tvardi Therapeutics, 2018-present

Member, Scientific Advisory Board, Lytix Biopharma, 2019-present

National Institutes of Health (NIH)

Chair, Experimental Immunology Study Section, National Cancer Institute (NCI), 1987-1990

ad hoc Member, 1987

ad hoc Member, Review of Experimental Immunology Branch, National Cancer Institute (NCI), 1993

ad hoc Member, Review of Biological Resources Branch and Laboratories of Immunogenetics and Immunopathology, National Institute of Allergy and Infectious Diseases (NIAID), 1995

ad hoc Member, Review of Laboratory of Immune Cell Biology, National Cancer Institute (NCI), 1995

Member, Board of Scientific Counselors, National Cancer Institute (NCI), 1996-2000

ad hoc Member, Immunobiology Study Section, 1996

Site Visit Committee Member, Laboratory of Experimental Immunobiology, National Cancer Institute (NCI), 1996

Site Visit Committee Member, Laboratory of Molecular Immunoregulation, National Cancer Institute (NCI), 1996

Member, Biologics Subcommittee of the Developmental Therapeutics Program Review Group, National Cancer Institute (NCI), 1997

Member, Progress Review Group (PRG) Expert Panel on Gene Therapy, National Cancer Institute (NCI), 1997

Member, Search Committee for Laboratory Chief, Experimental Immunology Branch, National Cancer Institute (NCI), 1997

Participant, AIDS Vaccine Research Committee Workshop, 1997

Site Visit Committee Member, Laboratory of Biochemical Physiology and the Laboratory of Immune Cell Biology, National Cancer Institute (NCI), 1997

Site Visit Committee Member, Laboratory of Tumor Immunobiology and Biology, National Cancer Institute (NCI), 1997

Member, Immunology Board of the U.S.-Japan Cooperative Medical Science Program, National Institute of Allergy and Infectious Diseases (NIAID), 1998-2001

Co-Organizer, Professor and Co-Chair, Think Tank in Cancer Biology, National Cancer Institute (NCI), 2003

Review Committee, Rapid Access to Intervention Development Program, National Cancer Institute (NCI), 2005

The American Association of Immunologists (AAI), Bethesda, MD

Member, Public Affairs Committee, 1994-1996

Member, 1994-present

Member, Program Committee, 1995-1996

Councilor, 1996-2003

Vice President, 2000-2001

President, 2001-2002

American Academy of Microbiology

Fellow, 1997-present

National Academy of Sciences (NAS)

Member, International Benchmarking of U.S. Research Fields Immunology Panel, 1997

Member, 1997-present

Prostate Cancer Foundation

Member, Scientific Advisory Board, CaP CURE (now the Prostate Cancer Foundation), 1998-2004

American Association for Cancer Research (AACR)

Member, 2000-present

Landon Basic Prize Selection Committee, 2004-2005

Council of Scientific Advisors Committee, 2006

Member, AACR and the Stand Up To Cancer (SU2C) Innovative Research Grants (IRG) Scientific Review Committee, 2010-present

Member, Board of Directors, 2014-2017

Fellow, 2014-present

Cancer Research Institute (CRI)

Associate Director, Scientific Advisory Council, 2004-2011

Director, 2011-present

American Association for the Advancement of Science (AAAS)

Member, 2006-present

Fellow, 2012-present

Institute of Medicine of the National Academies (IOM)

Member, 2007-present

National Academy of Medicine

Member, 2007-present

American Society of Clinical Oncology (ASCO)

Member, 2009-present

Society for Immunotherapy of Cancer (SITC)

Member, 2013-present

The New York Academy of Sciences

Member, 2015-present

The Blue Ribbon Panel for VP Biden’s National Cancer Moonshot

Member, 2016-2017

American Academy of Arts and Sciences

Fellow, 2017-present

National Academy of Inventors

Fellow, 2017-present

Member, Scientific Advisory Board, BioAtla, LLC

Local/State

The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX

Member, 2012-present

Clinical and Translational Sciences, Houston, TX

Member, 10/2013-present

 

 

DATE OF LAST CV UPDATE

6/11/2019